Patent and Technology License and Purchase Agreement



 Exhibit 10.68 

 

			
	 CONFIDENTIAL TREATMENT REQUESTED
	  	EXECUTION COPY

 PATENT AND TECHNOLOGY LICENSE AND PURCHASE AGREEMENT 

This Patent and Technology License and Purchase Agreement is entered into on 2 February, 2011 (“Signing Date”) by and between:

 Hansen Medical, Inc., a company duly incorporated under the laws of the State of Delaware, having its registered office at 800 East
Middlefield Road, Mountain View, CA 94043, USA (hereinafter referred to as “Hansen”), 
 and 

Koninklijke Philips Electronics N.V., a company duly incorporated under the laws of The Netherlands, having its registered office in Eindhoven, The
Netherlands and Philips Medical Systems Nederland B.V., a private company with limited liability and a Philips Healthcare company, having its registered office and its principal place of business at Veenpluis 4-6, 5684 PC, Best, The Netherlands
(acting jointly and severally and hereinafter individually and collectively referred to as “Philips”). 
 Hansen and Philips
are hereinafter also referred to individually as a “Party” and collectively as the “Parties.” 
 WHEREAS,
Hansen owns certain patents and other Intellectual Property (defined below) related to Fiber Optic Shape Sensing and Localization (“FOSSL”) Technology (defined below); 
 WHEREAS, Hansen has obtained rights to certain patents and other Intellectual Property related to FOSSL Technology from Luna Innovations, Inc. and Luna Technologies, Inc. (individually and collectively,
“Luna”) through the Hansen-Luna Agreement (defined below) and the Development and Supply Agreement (defined below); 
 WHEREAS,
Philips wishes to purchase certain Hansen patents and to acquire licenses to certain other Hansen patents and other Intellectual Property, all related to FOSSL Technology and Hansen is willing to sell and to license the same to Philips on the
conditions set forth herein; 
 WHEREAS, Philips wishes to acquire, and Hansen is willing to arrange for SPE (defined below) to provide to
Philips, a sublicense to practice under the patents and other Intellectual Property related to FOSSL Technology, which Hansen has licensed from Luna, on the conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual obligations and covenants contained herein, the Parties have agreed as follows: 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 1. Definitions. The following terms when used in this Agreement shall have the respective
meanings ascribed thereto below: 
 1.1 “Affiliate(s)” shall mean, with respect to a Party, any one or more
legal entities (i) owned or controlled by the Party or, (ii) owning or controlling the Party, or (iii) owned or controlled by the legal entity owning or controlling the Party, but any such legal entity shall only be considered an
Affiliate of a Party for as long as such direct or indirect ownership or control exists. For the purposes of this definition a legal entity shall be deemed to own or control another legal entity if more than 50% (fifty percent) of the voting stock
of the latter legal entity, ordinarily entitled to vote in the meetings of shareholders of that entity (or, if there is no such stock, more than 50% (fifty percent) of the ownership of or control in the latter legal entity), is held, directly or
indirectly, by the owning or controlling legal entity. 
 1.2 “Agreement” shall mean this Patent License and
Purchase Agreement, including all its exhibits and annexes. 
 1.3 “Buy Back Field” shall mean a field in which
Hansen receives nonexclusive rights and in which Hansen may exercise its rights to buy back IP from Philips if Philips fails to satisfy the Marketing Requirement for such field, pursuant to Section 4. The Buy Back Fields include: (a) the
Vascular Non-Robotic Field and the SDOF Vascular Robotics Field (collectively, the “Vascular Buy Back Field”); or (b) the Endoluminal Non-Robotic Field and the SDOF Endoluminal Vascular Robotics Field (collectively, the
“Endoluminal Buy Back Field”); or (c) the Orthopedics Field and the SDOF Orthopedics Robotics Field (collectively, the “Orthopedics Buy Back Field”). For the avoidance of doubt, if Hansen or SPE exercises its
buy back rights under Section 4.2 with respect to a particular Buy Back Field, Philips shall retain its rights hereunder or under the SPE-Philips Agreement within the SDOF Medical Robotics Field for all other Buy Back Fields for which Hansen or
SPE has not exercised its buy back rights under Section 4.2 and for all activities licensed hereunder or sublicensed under the SPE-Philips Agreement within the SDOF Medical Robotics Field that are outside the Buy Back Fields. 

1.4 “Capture Period” shall mean the period commencing as of the Closing Date and ending [***] after the Closing Date;
provided, however that (a) in the event of a Change of Control of a Party within [***] after the Closing Date, the other (non-acquired) Party may elect by written notice for the Capture Period with respect to such Party to end upon the date of
such Change of Control and (b) in the event of a Change of Control of a Party within the period commencing after [***] after the Closing Date and ending [***] after the Closing Date, either Party may elect by written notice for the Capture
Period to end with respect to both Parties (i.e., for all circumstances where the term “Capture Period” is used in this Agreement) upon the date of such Change of Control. 

1.5 “Change of Control” shall mean with respect to a Party (a) the sale of all or substantially all of the assets
of such Party to which this Agreement relates to a Third Party, or (b) a merger, consolidation or other reorganization of such Party which results in more than 50% (fifty percent) of the voting stock of the resulting or surviving entity being
owned or held by 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT
REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 2 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
persons other than those owning or holding the voting stock in such Party immediately prior to such transaction, or (c) the sale by one or more stockholders of such Party, in a single
transaction or series of related transactions, of more than 50% (fifty percent) of the voting stock of such Party to one or more third parties who are at the time of such sale unaffiliated with any stockholders of such Party. 

1.6 “Closing” shall have the meaning given to such term in Section 3.1 below. 

1.7 “Closing Date” shall have the meaning given to such term in Section 3.1 below. 

1.8 “Colonoscopy Non-Robotic Field” shall mean [***]. 

1.9 “Development and Supply Agreement” shall mean the agreement entitled “Development and Supply Agreement”
between Hansen and Luna Innovations, Inc. dated January 12, 2010, as amended pursuant to Amendment No. 1 to Development and Supply Agreement dated as of February 17, 2010 and Amendment No. 2 to Development and Supply Agreement
dated as of April 2, 2010 (and as may be amended from time to time by other, later amendments, provided that the rights given to Philips under this Agreement shall not be affected by such other, later amendment(s)). 

1.10 “Endoluminal Non-Robotic Field” shall mean [***]. 

1.11 “Fiber Optic Shape Sensing Localization Technology” or “FOSSL Technology” shall mean [***].

 1.12 “FOSSL Enabled Product Payment” shall mean the [***] payment due by Philips for the sale of FOSSL
Systems. The FOSSL Enabled Product Payment is limited by the conditions stated in Section 3.3. 
 1.13 “FOSSL
IP” shall mean the Purchased Hansen Patents and Licensed Patents, and all other Licensed Hansen IP and Licensed Luna IP. FOSSL IP includes copyrighted or copyrightable works, object code, source code, and manuals (in all such cases which
otherwise fall within the foregoing definition) to the extent described in Section 2.4. 
 1.14 “FOSSL System”
shall mean a Product, which (a) includes an [***] , (b) but for the licenses granted and rights purchased hereunder or under [***] would infringe or violate, or whose use would infringe or violate FOSSL IP, and (c) is developed,
manufactured or sold by or for Philips or its present or future Affiliate or its or their licensees or sublicensees for or to a customer (i) in a member country of the [***] or in the [***] and/or (ii) in any country where [***]. For
avoidance of doubt: In the context of Section 3.3, a [***]. Additionally, for avoidance of doubt, [***] that do not meet all of (a), (b) and (c) in the foregoing are not considered a FOSSL System in the context of Section 3.3.

 1.15 “Hansen Group 1 Patents” shall mean the patent applications and patents listed on Exhibit E; together
with any renewal, division, continuation, continued prosecution 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 3 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
application or continuation-in-part of any of such patents, certificates and applications, any and all patents or certificates of invention issuing thereon, and any and all reissues,
reexaminations, extensions, divisions, provisional filings, parent applications, renewals, substitutions, confirmations, registrations and revalidations of or to any of the foregoing, and any foreign counterparts of any of the foregoing. 

1.16 “Hansen Group 2 Patents” shall mean the patent applications and patents listed on Exhibit F; together with any
renewal, division, continuation, continued prosecution application or continuation-in-part of any of such patents, certificates and applications, any and all patents or certificates of invention issuing thereon, and any and all reissues,
reexaminations, extensions, divisions, provisional filings, parent applications, renewals, substitutions, confirmations, registrations and revalidations of or to any of the foregoing, and any foreign counterparts of any of the foregoing, in each
case to the extent claiming any FOSSL Technology, including any part, aspect, feature or embodiments of any FOSSL Technology. 

1.17 “Hansen Group 3 Patents” shall mean the patent applications and patents listed on Exhibit G; together with any
renewal, division, continuation, continued prosecution application or continuation-in-part of any of such patents, certificates and applications, any and all patents or certificates of invention issuing thereon, and any and all reissues,
reexaminations, extensions, divisions, provisional filings, parent applications, renewals, substitutions, confirmations, registrations and revalidations of or to any of the foregoing, and any foreign counterparts of any of the foregoing, in each
case to the extent claiming any FOSSL Technology, including any part, aspect, feature or embodiments of any FOSSL Technology. 

1.18 “Hansen-Intuitive Cross License Agreement” shall mean the Cross License Agreement between Intuitive Surgical, Inc.
and Hansen, effective as of January 12, 2010. 
 1.19 “Hansen-Luna Agreement” shall mean the agreement
entitled “License Agreement Between Hansen and Luna” dated January 12, 2010. 
 1.20 “Hansen
Product” shall mean any Product developed, made or commercialized by or for Hansen or its Affiliates in any country or territory in the world (or any component or subsystem thereof). 

1.21 “Intellectual Property” or “IP” shall mean: 

(i) inventions and discoveries, whether patentable or not, all patents, registrations, invention disclosures and applications therefor,
including divisions, continuations, continuations-in-part and renewal applications, and including renewals, extensions and reissues; 
 (ii) Trade Secrets; 
 (iii) to the extent not meeting the definition of Trade
Secrets, other confidential information, know-how, processes, schematics, business methods, formulae, drawings, prototypes, models, designs, customer lists and supplier lists; 

  
 4 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 (iv) published and unpublished works of authorship, whether copyrightable or not,
including, without limitation, databases or other compilations of information), copyrights therein and thereto, and registrations and applications therefor, and all renewals, extensions, restorations and reversions thereof; and 

(v) all other generally recognized intellectual property or proprietary rights (excluding trademarks and similar rights in marks, names
and logos). 
 1.22 “Interrogator” shall mean [***]. 

1.23 “Intuitive-Luna Agreement” shall mean that certain Development and Supply Agreement dated June 11, 2007
between Intuitive Surgical, Inc. (“Intuitive”) and Luna Innovations Incorporated, as restated and amended by Luna and Intuitive as of January 12, 2010 pursuant to the Amendment to the 2007 Development and Supply Agreement.

 1.24 “IP Security Agreement” shall mean the Intellectual Property Security Agreement between SPE and Philips
securing certain obligations of SPE to Philips under the SPE-Philips Agreement. 
 1.25 “Licensed Fields” shall
mean the Vascular Non-Robotic Field, the Endoluminal Non-Robotic Field, the Non-Robotic Medical Devices Field (including the Colonoscopy Non-Robotic Field), the Orthopedics Field, and the SDOF Medical Robotics Field. 

1.26 “Licensed Hansen IP” shall mean: 
 (a) (i) the Licensed Hansen Patents and (ii) any and all patent applications and patents owned by Hansen or its controlled Affiliates (excluding any intellectual property developed with or for
Third Parties other than Luna) and filed [***] and claiming inventions developed solely by Hansen (or jointly with Luna), in each case to the extent claiming or covering any FOSSL Technology, or enabling the integration of FOSSL Technology within a
Sensor, including all patent applications (and patents issuing from those applications) filed [***] that claim priority back to any Licensed Hansen Patents (as well as patents issuing on such patent applications filed prior to the end of the Capture
Period); but excluding, for the avoidance of doubt, patents and patent applications on inventions conceived or first reduced to practice [***]. Any patent applications and patents described above in Section 1.26(a)(ii) shall be allocated to
either the Hansen Group 2 Patents or the Hansen Group 3 Patents pursuant to the following. Hansen shall provide to Philips on [***] (or as frequently as the Parties may otherwise agree upon in writing) an update of schedules for the Hansen Group 2
Patents and the Hansen Group 3 Patents, [***]. All terms and conditions applicable to the designated group shall apply respectively to the new patent rights. [***]). Notwithstanding the foregoing, with respect to patents and patent applications
meeting the foregoing definitions of this Section 1.26(a), Licensed Hansen IP described in this Section 1.26(a) only includes the claims of such patents and patent applications to the extent claiming any FOSSL Technology, including any
part, aspect, feature or embodiments of any FOSSL 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 5 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Technology. Therefore, Licensed Hansen IP described in this Section 1.26(a) excludes any claims of patents or patent applications that do not claim any subject matter that is not FOSSL
Technology or embodiments of FOSSL Technology. 
 (b) all FOSSL Technology (including, without limitation, all Intellectual
Property therein or thereunder) other than the patent applications and patents described in clause (a) or the Licensed Luna IP, which are created, invented or reduced to practice by Hansen (solely or jointly with Luna) under the Development and
Supply Agreement [***] under any other agreement between Hansen and Luna [***] and are for use in the Licensed Fields, or are otherwise within the control of Hansen pursuant to the Development and Supply Agreement or [***] under any other agreement
between Hansen and Luna [***]. For the further avoidance of doubt, the Licensed Hansen IP includes the Hansen Group 2 Patents and the Hansen Group 3 Patents, and excludes any Hansen patents and patent applications that are (i) filed prior to
the Closing Date that are not part of the Licensed Hansen Patents or (ii) filed after the Closing Date but claim only priority to a patent or patent application that was filed prior to the Closing Date and are not part of the Licensed Hansen
Patents. 
 1.27 “Licensed Hansen Patents” shall mean the Hansen Group 2 Patents and the Hansen Group 3
Patents. 
 1.28 “Licensed Luna IP” shall mean, subject to Section 2.2 of the SPE-Philips Agreement regarding
NASA IP: (a) the Licensed Luna Patents and (b) any and all FOSSL Technology created, invented or reduced to practice by Luna (together with all intellectual and industrial property rights of any sort throughout the world therein or
thereunder) other than the Licensed Luna Patents, in each case which are licensed (with a right to sublicense) to Hansen (or SPE after the Closing) by Luna pursuant to the Hansen-Luna Agreement. [***] 

1.29 “Licensed Luna Patents” shall mean, subject to Section 2.2 of the SPE-Philips Agreement regarding NASA IP, any and
all patents, inventors’ certificates and patent applications throughout the world to the extent claiming, or which would (absent a license) be infringed by the manufacture, use or sale of, any FOSSL Technology, in each case which are licensed
(with a right to sublicense) to Hansen (or SPE after the Closing) by Luna pursuant to the Hansen-Luna Agreement, including without limitation those listed patent applications and patents set forth in Exhibit B, and any patents or patent applications
of Luna which claim, or which would (absent a license) be infringed by the manufacture, use or sale of, the subject matter in Exhibit C; together with any renewal, division, continuation, continued prosecution application or continuation-in-part of
any of such patents, certificates and applications, any and all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations and
revalidations of or to any of the foregoing, and any foreign counterparts of any of the foregoing, in each case to the extent claiming, or which would (absent a license) be infringed by the manufacture, use or sale of, any FOSSL Technology. [***]

  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND
SEPARATELY FILED WITH THE COMMISSION. 

  
 6 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.30 “Licensed Patents” shall mean the Licensed Hansen Patents and the
Licensed Luna Patents. 
 1.31 “Luna-Philips Joint Development Agreement” shall mean any future agreement
between Luna and Philips (or a present or future Affiliate of Philips) in effect within the Capture Period, whereby Luna and Philips (or its Affiliates) jointly develop technology (and/or Luna develops technology for Philips) in the field of FOSSL
Technology. 
 1.32 “Medical Robotics Field” shall mean [***]. 

1.33 “Naked License” or “Naked Sublicense” shall mean a license or sublicense that is under the FOSSL
IP to a Third Party in a transaction [***]. Each Naked License and Naked Sublicense granted by Philips must be consistent with the terms and conditions of this Agreement, including Articles 3 and 13, and the SPE-Philips Agreement (as applicable).
For the avoidance of doubt, only Philips may grant Naked Licenses or Naked Sublicenses hereunder. Hansen and the SPE are not entitled to grant a Naked License or Naked Sublicense relating to any FOSSL IP to any Third Party in the Licensed Fields
except as set forth in this Agreement and the SPE-Philips Agreement. [***] 
 1.34 “NASA” shall mean the U.S.
National Aeronautics and Space Administration. 
 1.35 “NASA IP” shall mean the portion of the intellectual
property licensed to Luna pursuant to the NASA License and sublicensed by Luna to Hansen pursuant to, and subject to the terms and conditions of, the Hansen-Luna Agreement, including the patents listed on Exhibit D. 

1.36 “NASA License” shall mean that certain License Agreement No. DN-982 by and between the United States of America
(NASA) and Luna Innovations Incorporated dated June 10, 2002, including the modification dated January 23, 2006. 

1.37 “Non-Robotic Medical Devices Field” shall mean [***]. 

1.38 “Orthopedics Field” shall mean [***]. 
 1.39 “Out-Licensing Payments” shall mean the payments due by Philips to Hansen pursuant to Section 3.5 and SPE pursuant to Section 3.3 of the SPE-Philips Agreement for any Naked
License or Naked Sublicense or cross license described in Section 3.5 or Section 3.3 of the SPE-Philips Agreement under any of the FOSSL IP rights of Philips (including to the Licensed Luna IP or Licensed Hansen IP) acquired under this
Agreement or the SPE-Philips Agreement. 
 1.40 “Philips FOSSL IP” shall mean (a) all FOSSL patents and
patent applications solely owned by Philips or its Affiliates that were created, invented or reduced to practice by employees or agents of Philips or its Affiliates after the Closing Date and [***] and (b) all FOSSL Technology other than the
FOSSL patents and patent applications described in clause (a), which are created, invented or reduced to practice by Philips or its Affiliates (solely or 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 7 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
jointly with Luna) under the Luna-Philips Joint Development Agreement after the Closing Date [***], and are for use in the fields licensed to Hansen in Section 2.5; together with all patent
applications (and patents issuing from those applications) filed [***] that claim priority back to any patent application filed [***] and included in the description above (as well as patents issuing on such patent applications filed prior to the
end of the Capture Period); [***]. Notwithstanding the foregoing, with respect to patents and patent applications meeting the foregoing definitions, Philips FOSSL IP only includes the claims of such patents and patent applications to the extent
claiming any FOSSL Technology, including any part, aspect, feature or embodiments of any FOSSL Technology; [***]. For the avoidance of doubt, no Intellectual Property owned, controlled, or conceived by Philips or its Affiliates prior to the Closing
Date shall be included within Philips FOSSL IP. 
 1.41 “Product(s)” shall mean any device, instrument,
diagnostic, therapeutic, product, system, application, or service. For the avoidance of doubt, it is the Parties’ understanding that consumables are included within Product. 

1.42 “Purchased Hansen Patents” shall mean the Hansen Group 1 Patents. 

1.43 “Reasonably Perceived Net Value” shall have the meaning given to such term in Section 3.5.1. 

1.44 “Royalty Reporting Form” shall mean a written statement in the form as attached hereto as Annex 1 signed by a duly
authorized officer on behalf of Philips. 
 1.45 “SDOF Medical Robotics Field” shall mean [***]. 

1.45.1 “SDOF Endoluminal Robotics Field” shall mean [***]. 

1.45.2 “SDOF Orthopedics Robotics Field” shall mean [***]. 

1.45.3 “SDOF Vascular Robotics Field” shall mean [***]. 

1.46 “Security Agreement” shall mean the Security Agreement between SPE and Philips securing certain obligations of SPE
to Philips under the SPE-Philips Agreement. 
 1.47 “Sensor” shall mean [***]. 

1.48 “Signing Date” shall have the meaning given to such term on the first page of this Agreement. 

1.49 “SPE” shall mean ECL7, LLC, a Delaware limited liability company. 

1.50 “Technology” shall mean any technical information, know-how, processes, procedures, methods, formulae, protocols,
techniques, software, computer code (including both object and source code), documentation, works of authorship, data, designations, designs, 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 8 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
devices, prototypes, substances, components, inventions (whether or not patentable), mask works, ideas, trade secrets and other information or materials, in tangible or intangible form.

 1.51 “Term” shall have the meaning set forth in Section 13.1 below. 

1.52 “Third Party” shall mean any entity other than a Party or an Affiliate of a Party. 

1.53 “Trade Secret” shall mean information and know-how to the extent that such information or know-how (a) derives
independent economic value, actual or potential, from not being generally known to the public or to other persons who can obtain economic value from its disclosure or use and (b) is the subject of efforts that are reasonable under the
circumstances to maintain its secrecy. Trade Secrets may include, but is not limited to confidential information, know-how, processes, schematics, business methods, formulae, drawings, prototypes, models, designs, customer lists and supplier lists
that meet the foregoing definition. 
 1.54 “Vascular Non-Robotic Field” shall mean [***]. 

2. License and Transfer of Rights 
 2.1 License Grants to Hansen Intellectual Property 
 2.1.1 Non-Robotic
Medical Devices Field; SDOF Medical Robotics Field. Subject to the terms and conditions of this Agreement and prior Hansen commitments specified in Exhibit H and in the Hansen-Luna Agreement, Hansen hereby grants to Philips and its present and
future Affiliates, effective as of the Closing, a nonexclusive, worldwide, transferable (subject to Section 17 of this Agreement) license under the Licensed Hansen IP to research, develop, make, have made, use, have used, import, sell, have sold and
otherwise commercialize and exploit Products in each case solely within the Non-Robotic Medical Devices Field (which includes, for the avoidance of doubt, the Colonoscopy Non-Robotic Field) and SDOF Medical Robotics Field. To avoid doubt, the
foregoing license shall be subject to the rights and licenses granted by Hansen to Intuitive under the Hansen-Intuitive Cross License Agreement (including Section 2.1 of the Hansen-Intuitive Cross License Agreement); and subject to the terms
and conditions of such agreement, Intuitive shall continue to enjoy its rights and licenses thereunder. 
 2.1.2 Vascular
Non-Robotic Field, Endoluminal Non-Robotic Field and Orthopedics Field. Subject to the terms and conditions of this Agreement and prior Hansen commitments specified in Exhibit H, Hansen hereby grants to Philips and its present and future
Affiliates, effective as of the Closing, a worldwide, transferable (subject to Section 17 of this Agreement) license (with the right to sublicense through one or multiple tiers solely as set forth in this Section 2.1.2 below) under the Licensed
Hansen IP to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products in each case solely within the Vascular Non-Robotic Field, Endoluminal Non-Robotic Field and Orthopedics Field.
The foregoing license shall be exclusive with respect to the Hansen Group 2 Patents (subject to the rights of Luna and Intuitive under the Hansen-Luna Agreement and 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 9 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Hansen-Intuitive Cross License Agreement) and nonexclusive with respect to all other licensed Hansen patents and patent applications (including, to be clear, the Hansen Group 3 Patents).

 2.1.3 Covenant Not to Sue. For the avoidance of doubt, Hansen (for itself and on behalf of its controlled Affiliates
or other Hansen Affiliates that have acquired FOSSL IP from Hansen) hereby covenants to Philips (and its present and future Affiliates), for so long as and to the extent any licenses granted under this Agreement remain in effect, (i) not to sue
Philips and its Affiliates for infringement or misappropriation of any Intellectual Property covering FOSSL Technology in the Licensed Fields, and (ii) not to challenge Philips’ (or its present and future Affiliates’) rights to
market, use, or generally exploit FOSSL Technology in the applicable Licensed Fields. This Section 2.1.3 shall not bar suit against Philips or against any Philips Affiliate by any acquiror of Hansen (or any affiliate of such acquiror) by a
Change of Control of Hansen and based on infringement or misappropriation of any Intellectual Property (a) owned or controlled by such acquiror or its Affiliates immediately before such acquisition or (b) created, developed or reduced to
practice after such acquisition and not claiming priority to patents or patent applications included in the FOSSL IP as of the date of such acquisition. For the avoidance of doubt, this Section 2.1.3 shall only apply to pre-existing
intellectual property that is owned or controlled by Hansen immediately before a Change of Control of Hansen to the extent such intellectual property covers FOSSL Technology in the applicable Licensed Fields; other intellectual property that is
owned or controlled by an acquiror or entity controlling Hansen after a Change of Control (or their affiliates), and any intellectual property invented, created, developed, acquired, licensed or otherwise controlled by such acquiror or entity (or
their affiliates) after such Change of Control of Hansen, are not subject to the covenant not to sue of this Section 2.1.3. 
 2.1.4 Results of Development and Supply Agreement. For the avoidance of doubt, the licenses and sublicenses granted to Philips under this Agreement include access to and the right to use the
results of Hansen’s and Luna’s continuing work [***] under the Luna-Philips Joint Development Agreement (if any) subject to and to the extent of Hansen’s rights thereto pursuant to the Hansen-Luna Agreement. 

2.1.5 Further Transfers of Licensed Hansen IP. In the event that Hansen would sell, assign or otherwise transfer ownership in any
of the Licensed Hansen IP to an Affiliate or a Third Party, Hansen shall explicitly stipulate that the rights and licenses granted to Philips and its present and future Affiliates pursuant to this Agreement shall remain in force and any transfer or
assignment not so construed shall be null and void. An identical obligation shall be imposed by Hansen on the acquirer, including the obligation to impose the same on every subsequent acquirer or assignee. 

2.2 PURCHASED HANSEN PATENTS 
 2.2.1 Assignment. Subject to the terms and conditions of this Agreement (including without limitation the payment required by Section 3.2) and prior Hansen commitments (including any licenses
or other rights granted by Hansen prior to the Signing Date) regarding the Purchased Hansen Patents (each of which prior Hansen commitments are listed in Exhibit H and 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 10 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
in the Hansen-Luna Agreement), at the Closing, Hansen shall sell to Philips all right, title and interest in the Purchased Hansen Patents and shall execute the associated assignment form found at
Annex 2. Until Hansen transfers all patent files directly associated with the Purchased Hansen Patents, Hansen shall maintain all patent files directly associated with the Purchased Hansen Patents in good standing. To avoid doubt, the Purchased
Hansen Patents shall remain subject to any rights or licenses granted under such Purchased Hansen Patents under (and the applicable terms and conditions of) the agreements listed in Exhibit H. To further avoid doubt, the foregoing assignment shall
be subject to the rights and licenses granted by Hansen (a) to Luna under the Hansen-Luna Agreement (including Section 2.2(b) of the Hansen-Luna Agreement) and (b) to Intuitive under the Hansen-Intuitive Cross License Agreement
(including Section 2.1 of the Hansen-Intuitive Cross License Agreement); and subject to the terms and conditions of each of such agreements, each of Luna and Intuitive shall continue to enjoy its rights and licenses thereunder. 

2.2.2 Grantback License. Effective as of the Closing, Philips hereby grants to Hansen and its Affiliates a world-wide,
royalty-free, exclusive (subject to Philips’ nonexclusive retained rights to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products in each case solely within SDOF Medical
Robotics Field), irrevocable license under the Purchased Hansen Patents for the lifetime of each patent right, to use and practice the Purchased Hansen Patents for and in any and all activities and applications in the SDOF Medical Robotics Field,
Medical Robotics Field and in any Buy Back Field for which Hansen has exclusive or nonexclusive rights pursuant to Section 4.2 that Hansen or its Affiliates (or any of their respective sublicensees) see fit, including, without limitation, the
right to research, develop, make, have made, use, have used, import, sell, have sold, offer to sell and otherwise commercialize and exploit any Product (including software), process or service including the right to have any such Product, process or
service made for it and/or its Affiliates or sold or otherwise disposed of for it or its Affiliates by third parties and to grant to Luna and Intuitive rights under the Purchased Hansen Patents to enable the continued grant of rights with respect to
the Purchased Hansen Patents as set forth in the Hansen-Luna Agreement and the Hansen-Intuitive Cross License Agreement. Subject to Intuitive’s rights under the Hansen-Intuitive Cross License Agreement or Luna’s rights under the
Hansen-Luna Agreement, with respect to the SDOF Medical Robotics Field, the foregoing license shall be sublicenseable by Hansen (through one or multiple tiers) solely in connection with Hansen Products, and sublicensees shall not have the right to
enforce the licensed rights. Subject to Intuitive’s rights under the Hansen-Intuitive Cross License Agreement or Luna’s rights under the Hansen-Luna Agreement, with respect to the Medical Robotics Field outside of the SDOF Medical Robotics
Field, the foregoing license shall be sublicenseable by Hansen (through one or multiple tiers) in connection with any Products. To avoid doubt, (a) Luna has and shall have the right to sublicense (through one or multiple tiers) the Purchased
Hansen Patents outside the Medical Robotics Field, outside the Orthopedics Field, outside the Vascular Non-Robotic Field and outside the Endoluminal Non-Robotic Field (and within such excluded fields solely to the extent of the scope of Luna’s
retained rights expressly described in the Hansen-Luna Agreement) as set forth in Section 2.2(b) of the Hansen-Luna Agreement; and (b) Intuitive has and shall have the right to sublicense (through one or multiple tiers) the Purchased
Hansen Patents within the 

  
 11 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Medical Robotics Field as set forth in Section 2.1 of the Hansen-Intuitive Cross License Agreement. 
 2.2.3 Further Transfers of Purchased Hansen Patents. In the event that Philips would sell, assign or otherwise transfer ownership in any of the Purchased Hansen Patents to an Affiliate or a Third
Party, Philips shall explicitly stipulate that (a) such transfer shall be subject to any rights or licenses granted under such Purchased Hansen Patents under (and the applicable terms and conditions of) the agreements listed in Exhibit H and
the Hansen-Luna Agreement and (b) the rights and licenses granted to Hansen and its Affiliates pursuant to this Agreement shall remain in force, and any transfer or assignment not so construed shall be null and void. An identical obligation
shall be imposed by Philips on the acquirer, including the obligation to impose the same on every subsequent acquirer or assignee. 
 2.3 Acknowledgement Regarding Agreements Among Hansen, Luna and Intuitive. Philips has reviewed the agreements provided by Hansen listed in Exhibit H. Based on these agreements, Philips
acknowledges as follows: The licenses granted under the Licensed Hansen IP pursuant to Section 2 of this Agreement, to the extent they include (or come to include) sublicenses under patents or Technology of a Third Party, shall be subject to
the terms and conditions of the agreement governing the license under which the sublicense is granted. Philips agrees (a) that the Purchased Hansen Patents and the Licensed Hansen IP licensed to Philips hereunder is subject to the terms and
conditions of the Development and Supply Agreement, (b) to materially comply with the terms and conditions of the Development and Supply Agreement as a licensee of Hansen and (c) this Agreement shall not prevent or prohibit Hansen and Luna
from entering into other development and supply agreements between them provided that such agreements are not inconsistent with any other term of this Agreement. Further, Philips acknowledges and agrees that the rights licensed to Philips hereunder
shall be subject to the rights and licenses granted by Hansen to Intuitive pursuant to the Hansen-Intuitive Cross License Agreement and subject to certain limited rights and licenses retained by and/or granted to Luna pursuant to the Hansen-Luna
Agreement and the Development and Supply Agreement. 
 2.4 Clarification Regarding Copyrights. With respect to Technology
licensed by Hansen to Philips under this Agreement that includes software, works of authorship or copyrighted materials, such licenses shall include the right to copy, modify and make derivative works thereof (and the right to use any ideas,
concepts, algorithms and other information contained therein) within the fields and pursuant to the terms and conditions otherwise provided in this Agreement, regardless of when or whether provided or disclosed to Philips. The foregoing shall not be
construed to require the delivery or provision of any particular software (or source code), works of authorship or copyrighted materials except to the extent specifically provided in this Agreement or otherwise agreed upon in writing by the Parties.

 2.5 Philips FOSSL IP. Effective as of the Closing, Philips hereby grants to Hansen and its present and future
Affiliates a nonexclusive, worldwide, transferable (subject to Section 17 of this Agreement) license (with the right to sublicense through one or multiple tiers solely for 

  
 12 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Hansen Products) under the Philips FOSSL IP to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products, in each case solely
within the Medical Robotics Field (including, to avoid doubt, the SDOF Medical Robotics Field). On a [***] basis following the Closing, Philips shall report to Hansen any patent applications filed relating directly to the Philips FOSSL IP. All terms
and conditions applicable to the Philips FOSSL IP shall apply to the newly issued patents. 
 2.6 Reservation of Rights.
Except for the rights and licenses expressly granted to Philips hereunder, Hansen shall retain all right, title and interest in and to: (a) the Licensed Hansen IP and all of Hansen’s other Intellectual Property; and (b) as between the
Parties, all of Hansen’s right, title and interest in and to the Licensed Luna IP. Hansen does not grant to Philips any rights or licenses in or to any patents, Technology or other intellectual property, whether by implication, estoppel, or
otherwise, except to the extent expressly provided in this Agreement. 
 2.7 Philips-Luna Agreement. Based on
Philips’ representation to Hansen, Hansen hereby consents and acknowledges that Philips entered into a springing direct license with Luna for Licensed Luna IP (i.e., a license from Luna to Philips for Licensed Luna IP (of the same scope as the
license therefor under this Agreement) which will become effective immediately without any further action by Philips, if and to the extent the Hansen-Luna Agreement is terminated, or if rejected by reason of any bankruptcy, insolvency, or other
creditor arrangement or proceeding commenced by or against Hansen or its Affiliates. Hansen also consents and acknowledges that Philips may enter into its own development agreements with Luna in the Non-Robotic Medical Devices Field and SDOF Medical
Robotics Field (as those terms are defined in the Hansen-Luna Agreement), and that Hansen consents to such agreements, subject to any rights it may have under the Hansen-Luna Agreement and the Development and Supply Agreement, and provided that any
agreement by either Party with Luna shall not be inconsistent with the other Party’s agreements with Luna, including without limitation [***] of the Hansen-Luna Agreement. 
 3. Payment and Reporting 
 3.1 Closing.
Subject to the terms and conditions hereof, the consummation of the sale of Purchased Hansen Patents and the effectiveness of the licenses granted hereunder (the “Closing”) will take place at 10:00 a.m. (EST) on the third (3rd) Business Day following the date on which all of the conditions
set forth in Section 10.4 have been satisfied or waived (other than any such conditions that by their terms cannot be satisfied until the Closing Date, which conditions shall be required to be so satisfied or waived on the Closing Date), unless
another time and/or date is agreed to in writing by Hansen and Philips (the “Closing Date”). The Closing shall be held at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston,
Massachusetts, unless another place is agreed to in writing by the Parties hereto. 
 3.2 Initial Payment. At the
Closing, Philips shall pay to Hansen an initial non-refundable, non-creditable payment of [***]. Until such payment is made by Philips, no licenses 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 13 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
or assignments granted under this Agreement shall be deemed effective. The Parties acknowledge that, subject to the terms and conditions of the SPE-Philips Agreement, Philips is required to make
a separate initial payment of [***] to SPE in consideration of the rights granted with respect to the Licensed Luna IP under the SPE-Philips Agreement. 
 3.3 FOSSL Enabled Product Payments. In further consideration of the rights granted hereunder by Hansen to Philips, following the Closing, Philips shall make a royalty payment in the
form of a FOSSL Enabled Product Payment to Hansen for each calendar year [***] (or as otherwise shifted for a specific Licensed Field in accordance with the terms of Section 3.3.1) for the [***] FOSSL System ([***] and for each unit of FOSSL
Systems delivered to and accepted by Philips’ (or its Affiliates’ or their respective licensees’ or sublicensees’) customers in excess of [***] in that respective year. The FOSSL Enabled Product Payment shall be made [***]. For
all FOSSL Systems for which a FOSSL Enabled Product Payment is due, the FOSSL Enabled Product Payments made in a given calendar year shall be an amount which is equal to [***] (due within [***] of receiving an invoice for the amount due after the
delivery and acceptance of the [***] FOSSL System in the applicable calendar year when [***]) plus [***] for each delivered and accepted FOSSL System after the total of such deliveries during the applicable calendar year reaches [***]. [***]

 3.3.1 Extension. If any Buy Back Period is extended or tolled pursuant to Section 4.3 and/or Section
4.4, the time period during which FOSSL Enabled Product Payments are due under Section 3.3 shall be extended with respect to that specific Licensed Field for an amount of time equivalent to the amount by which any Buy Back Period is so extended
or tolled. For avoidance of doubt, if the Vascular Buy Back Period is extended for six (6) months, the payment period of Section 3.3 would be extended for six (6) months for sales in the Vascular Non-Robotic Field only. 

3.4 Reduction Due to Royalty Stacking. In the event that Philips reasonably believes that it is required to make any
royalty or similar payments to a Third Party for FOSSL Technology in order to exploit the licenses granted under Article 2 to Philips for Licensed Hansen IP and/or under Article 2 of the SPE-Philips Agreement for Licensed Luna IP, Philips may deduct
from the FOSSL Enabled Product Payments payable to Hansen pursuant to Section 3.3 of this Agreement or Section 3.2 of the SPE-Philips Agreement, [***] of such royalties paid to such Third Parties, but in no event may the royalties payable
to Hansen under this Agreement and to the SPE under the SPE-Philips Agreement be reduced by more than [***] as a result of this Section 3.4. 
 3.5 Naked (Sub)licenses and Cross Licenses. 
 3.5.1 If Philips
or its Affiliates enters into a Naked License or Naked Sublicense based on the FOSSL IP then Philips shall pay [***] to Hansen ( [***]), if and when that value is realized by Philips or its present or future Affiliates. The “Reasonably
Perceived Net Value” ([***]) shall include [***]. Philips will notify Hansen promptly, and in any event within [***] following the execution of any Naked License or Naked Sublicense, which will include a description of the terms of such
license, and will thereafter notify Hansen within [***] of receipt 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 14 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
of consideration therefrom, which will include a description and calculation of the Reasonably Perceived Net Value and [***] (e.g. reporting [***]). If Hansen disputes Philips’
Reasonably Perceived Net Value, the Parties may submit the dispute to a neutral Third Party [***]. The total of Out-Licensing Payments to Hansen (under this Agreement) and SPE (under the SPE-Philips Agreement) from Philips shall not in any
event, for any reason, exceed [***] Out-Licensing Payments will be due within [***] of receiving an invoice for such payment. With each Out-Licensing Payment, Philips shall provide Hansen a written report specifying in reasonable detail
the form of underlying revenue received or grant given and the calculation of any applicable exclusions specified in this Section 3.5. 
 3.5.2 If Philips or its present or future Affiliates enters into a cross-license based on the FOSSL IP, and the FOSSL IP is material to the cross license, then Philips shall pay [***] attributed to the
FOSSL IP ([***]). For the avoidance of doubt, Philips will not owe any payment to Hansen for cross licenses where the FOSSL IP is included [***] If Hansen disputes Philips’ Reasonably Perceived Net Value, the Parties may submit the dispute to a
neutral Third Party [***] 
 3.6 Limitation on Payments. Notwithstanding any provision herein, the FOSSL Enabled Product
Payment is limited to FOSSL Systems and shall not apply to any other product or process derived from the Licensed Hansen IP or Licensed Luna IP including, but not limited to, [***] that do not meet the definition of a FOSSL System. 

3.7 Wiring Instructions. All payments by Philips to Hansen under this Agreement shall be made by wire in U.S. Dollars to the
account designated by Hansen in writing. 
 3.8 Reporting. Subject to the extensions described in Section 3.3.1
above, within thirty (30) calendar days following [***] Philips shall submit to Hansen (even in the event that no FOSSL Systems have been manufactured or sold) a Royalty Reporting Form, duly completed by an authorized officer of Philips.
Royalty reports shall start with the first calendar quarter after shipment of the first FOSSL System for commercial sale, and end with the reporting period that ends [***] subject to the extensions described in Section 3.3.1 above. 

3.9 Timing; Late Payments. Together with submission of Philips’ Royalty Reporting Form, subject to Section 3.3, Philips
shall pay the corresponding FOSSL Enabled Payment due to Hansen hereunder within [***] of receiving an invoice for such payment. Any undisputed amounts not paid when due under this Agreement shall automatically accrue interest from the date when due
until actually paid at a rate equal to the sum of [***] plus the prime rate of interest quoted in the Wall Street Journal (West Coast edition) calculated daily on the basis of a 365-day year, or if such edition is unavailable, a similar
reputable data source; provided, however, that in no event shall such rate exceed the maximum annual interest rate permitted under applicable law. For the avoidance of doubt, the accrual of interest shall not apply to the initial payment due under
this Agreement. 
 3.10 Taxes. In the event that the governmental authorities of any country imposes any withholding
taxes on payments made by Philips to Hansen hereunder and requires Philips to 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 15 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
withhold such tax from such payments, Philips may reduce the payment due by the amount of such tax. In such event, Philips shall promptly provide Hansen with tax receipts issued by the relevant
tax authorities and with reasonable assistance in obtaining any credits for, and reductions to or exemptions from, such amounts. 
 3.11 Records. Philips shall (and shall ensure that its Affiliates and their respective licensees and sublicensees, as applicable) maintain complete, true and accurate books of accounts and records
reasonably sufficient for the purpose of determining the payments to be made to Hansen under this Agreement for at least [***] following the end of the calendar quarter to which they pertain. Hansen may at its own expense audit such books of account
limited to Philips’ (and its Affiliates’ and their respective licensees’ and sublicensees’) sale of the FOSSL Systems and the revenue and Licensing Out Costs described in Section 3.5 at the place where such books are kept, in
order to verify Philips’ royalty statements provided for in this Article 3. Any such audit shall be conducted only once per calendar year per set of books, upon at least 21 days prior written notice and by an independent professional auditor
reasonably acceptable to Philips and bound by written confidentiality obligations, during normal business hours and in such a manner as not to interfere unduly with normal business activities. A copy of any report made by such auditor shall be
delivered to Philips at the same time as such report is delivered to Hansen. No audit in respect of any royalty statement shall commence later than [***] from the date of such royalty statement, and only one audit shall be conducted in respect of
any such statement, except that if any material errors or discrepancies are uncovered during an audit, more audits shall be allowed until such material uncovered errors or discrepancies are resolved. Any materials created by the audit shall be
treated by Hansen and Philips as confidential information. 
 3.12 Reports in General. Philips’ royalty statements
and its accounting records shall be final and binding on Hansen unless (a) written detailed objection to them is given to Philips by Hansen within [***] from the date of the relevant statement and unless any action or proceedings in respect of
the same are commenced within twelve months from the date of such written objection, (b) an audit uncovers a material error or discrepancy or (c) such statements and records are the subject of fraud, gross negligence or a breach of this
Agreement. 
 3.13 Confidential Nature of Reports. The Royalty Reporting Forms provided by Philips to Hansen under this
Article 3 in writing and marked as Confidential shall be treated by Hansen as confidential. 
 3.14 Additional Payment
Reductions. In the event that all of the Licensed Patents and all of the Hansen Purchased Patents covering a FOSSL System are declared invalid by a court or governmental authority of competent jurisdiction (and from which decision no appeal is
taken or can be taken), Philips may deduct [***] of the amounts due from the FOSSL Enabled Product Payments payable to Hansen pursuant to [***] of this Agreement (and to SPE pursuant to [***] of the SPE-Philips Agreement) and the payments payable to
Hansen for the grant of a Naked License or Naked Sublicense pursuant to [***] of this Agreement (and to SPE for the grant of a Naked License or Naked Sublicense pursuant to [***] the SPE-Philips Agreement). 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 16 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 3.15 Additional Payment Reductions For Non-Patent FOSSL IP. For a given FOSSL
System, Naked License, Naked Sublicense or cross license (as described in Section 3.5 of this Agreement or Section 3.3 of the SPE-Philips Agreement), FOSSL Enabled Product Payments under Section 3.3 of this Agreement and
Section 3.2 of the SPE-Philips Agreement for such FOSSL System and Out-Licensing Payments for such Naked License, Naked Sublicense or cross license under Section 3.5 of this Agreement or Section 3.3 of the SPE-Philips Agreement will
be reduced by an additional [***] (a) the event described in Section 3.14 occurs and (b) the FOSSL System, Naked License, Naked Sublicense or cross license only includes non-patent FOSSL IP or FOSSL Technology that is not subject to
copyright protection, and: 
 a) was known to the general public before the Signing Date; 

b) was rightfully known by Philips or its present or future Affiliate before receipt from Hansen or Luna; 

c) becomes rightfully known to Philips or its present of future Affiliate from a source other than Hansen or Luna without breach of a
duty of confidentiality to Hansen or Luna or its Affiliates; or 
 d) is independently developed by Philips or its present or
future Affiliate without the use of or access to the confidential information or other FOSSL IP of Hansen or Luna. 
 For the sake of clarity,
in the event that both Sections 3.14 and 3.15 apply to a particular FOSSL System, Naked License, Naked Sublicense or cross license (as described in Section 3.5), [***] for FOSSL Enabled Product Payments or Out-Licensing Payments with respect to
such FOSSL System, Naked License, Naked Sublicense or cross license. 
 4. Anti-Shelving Provisions 

4.1 Marketing Requirement; Buy Back. Philips (or its present or future Affiliates) shall [***] of any FOSSL System in each Buy Back
Field for commercial sale and clinical use [***]) (the “Marketing Requirement”) in each of the following periods, subject [***] For the avoidance of doubt, Philips’ efforts with respect to satisfying or not satisfying the
Marketing Requirement shall apply with respect to application of this Article 4 of this Agreement and Article 4 of the SPE-Philips Agreement and the rights of Hansen and SPE under such articles. 

4.1.1 Vascular Buy Back Period. Subject to any applicable cure period in Section 4.2, or any extensions set forth in
Section 4.3, Philips (or its present or future Affiliates or their respective licensees or sublicensees) shall [***] (“Vascular Buy Back Period”). 
 4.1.2 Endoluminal Buy Back Period. Subject to any applicable cure period in Section 4.2, or any extensions set forth in Section 4.3, Philips (or its present or future Affiliates or their
respective licensees or sublicensees) shall [***]. The Marketing Requirement for the Endoluminal Buy Back Field shall also be met in the Endoluminal Buy Back Period [***] 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 17 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 4.1.3 Orthopedics Buy Back Period. Subject to any applicable cure period in
Section 4.2, or any extensions set forth in Section 4.3, Philips (or its present or future Affiliates or their respective licensees or sublicensees) shall [***] (“Orthopedics Buy Back Period”). The Marketing Requirement
for the Orthopedics Buy Back Field shall also be met in the Orthopedics Buy Back Period [***] 
 4.1.4 For avoidance of doubt,
such Marketing Requirements under this Section 4.1 in the respective Buy Back Fields are one time requirements for each applicable Buy Back Field. 
 4.2 Cure Periods. Philips shall have [***] after such time period to cure any Marketing Requirement deficiency. If Philips does not cure within such [***] period, then: (a) Philips shall grant
(and hereby grants, effective upon the end of the Vascular Buy Back Period for the Vascular Buy Back Field if the Marketing Requirement for (i) above is not met, upon the end of the Endoluminal Buy Back Period for the Endoluminal Buy Back Field
if the Marketing Requirement for (ii) above is not met, and upon the end of the Orthopedics Buy Back Period for the Orthopedics Buy Back Field if the Marketing Requirement for (iii) above is not met) a nonexclusive, worldwide,
transferable, royalty-free, fully paid up license (with the right to sublicense through one or multiple tiers) under the Purchased Hansen Patents and Licensed Hansen IP to Hansen and under the Licensed Luna IP to SPE to research, develop, make, have
made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products in each case solely within the applicable Buy Back Field(s) for which the Marketing Requirement has not been met within the time periods specified above;
(b) Philips hereby grants to Hansen (with respect to the foregoing license granted to Hansen) and to SPE (with respect to the foregoing license granted to SPE) the option (which must be exercised within [***] to convert the foregoing license
granted to Hansen and SPE in clause (a) from a nonexclusive license to an exclusive license (except with respect to the SDOF Endoluminal Robotics Field, SDOF Orthopedics Robotics Field and SDOF Vascular Robotics Field, for which Philips
acknowledges that the licenses granted to Philips in Section 2.1.1 of the SPE-Philips Agreement and Section 2.1.1 of this Agreement shall terminate), exercisable by written notice to Philips and payment [***] (“Buy Back
Price”); and (c) the scope of the licenses and rights granted to Philips for such Buy Back Field pursuant to this Agreement and the SPE-Philips Agreement shall be automatically adjusted with no further action required by the Parties to
reflect the license rights of Hansen and SPE under clauses (a) and/or (b) (e.g., the applicable licenses granted to Philips shall be terminated so that the corresponding rights revert back to Hansen and SPE (as applicable), together with
all rights to enforce the applicable patents in the applicable Buy Back Field, notwithstanding anything to the contrary set forth in Article 12). The Parties shall, however, agree upon which Party will prosecute and maintain any pending or future
patent or patent application(s) relating to the Licensed Patents. To be clear, with the exception of prosecution, if Hansen exercises its option for a Buy Back Field pursuant to clause (b), Philips shall thereafter have no rights under the FOSSL IP
licensed from Hansen or SPE for such Buy Back Field. 
 Any license granted by Philips to a Third Party under the applicable FOSSL IP or FOSSL
Technology up until the expiration of the Buy Back Period, however, will remain in force 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 18 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
(“Surviving Buy-Back Sublicense”) [***] and the Parties will reasonably agree on a case by case basis [***] under the Surviving Buy Back Sublicense and the scope of the Surviving
Buy Back Sublicense relative to the total Buy Back Field. The [***] that may thus result for the Buy Back Price is [***] 
 4.3
Potential Extension of Buy Back Periods. The Vascular Buy Back Period, Endoluminal Buy Back Period and Orthopedics Buy Back Period (each, a “Buy Back Period”) may be extended under either Section 4.3.1 or Section 4.3.2 but
not both. To be clear, if Philips elects to extend a Buy Back Period under Section 4.3.1, Philips may not also elect to extend the same Buy Back Period under Section 4.3.2, and vice versa. 

4.3.1 Potential Extension for Filing an Application. If Philips has [***] for any FOSSL System for commercial sale and clinical
use in a given Buy Back Field at least [***] prior to the expiration of the Buy Back Period for such Buy Back Field, Philips may elect by written notice to Hansen to extend the Buy Back Period for such Buy Back Field as follows: 

(i) if Philips has [***] for any FOSSL System in the [***] Buy Back Field at least [***] prior to the date which is [***] following the
Closing Date, Philips may elect for the [***] Buy Back Period to end [***] following the Closing Date; 
 (ii) if Philips has
[***] for any FOSSL System in the [***] Buy Back Field at least [***] prior to the date which is [***] following the Closing Date, Philips may elect for the Endoluminal Buy Back Period to end [***] following the Closing Date; and 

(iii) if Philips has [***] for any FOSSL System in the [***] Buy Back Field at least [***] prior to the date which is [***] following the
Closing Date, Philips may elect for the [***] Buy Back Period to end [***] following the Closing Date. 
 4.3.2 Other
Potential Extension. 
 (i) If Philips or its present or future Affiliates fails to meet the Marketing Requirement in the
[***] Buy Back Field, then Philips may, at its option (but is not required to) purchase an additional [***] extension of the [***] Buy Back Period for [***], or a [***] extension for [***]. Such payment shall be credited against [***] 

(ii) If Philips fails to meet the Marketing Requirement in the [***] Buy Back Field, then Philips may, at its option (but is not required
to) purchase an additional [***] extension of the [***] Buy Back Period for [***], or a [***] extension for [***]. Such payment shall be credited against [***]. 
 (iii) If the [***] of the Development and Supply Agreement is not met by Luna under the Development and Supply Agreement by [***], then the [***] term of the [***] Buy Back Period will be extended [***]
up to a maximum of [***] until such time as Hansen decides, in good faith, that [***] has been met. Philips shall not be entitled to any additional extension of 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 19 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
the Vascular Buy Back Period beyond the [***] extension, except when relying on Section 4.3.1 (i). 
 4.4 Tolling. Notwithstanding anything to the contrary set forth in this Agreement, if Philips is delayed or prevented from meeting the Marketing Requirement due to the institution of a legal claim
brought by a Third Party against Philips or its present or future Affiliates or administrative proceeding relating to the subject matter of this Agreement or the existence of licensing negotiations in connection with a potential legal claim brought
by a Third Party against Philips or its present or future Affiliates relating to the subject matter of this Agreement, the Buy Back Period shall be tolled until such reason for Philips’ inability to meet the Marketing Requirement is eliminated.

 5. Source Code Escrow. During the period commencing on the Closing Date and ending fifteen (15) years thereafter, Hansen shall
deposit and maintain in escrow all source code within the Licensed Hansen IP and Licensed Luna IP (and documentation, libraries, tools, utilities and other related materials reasonably necessary for the installation, testing, deployment, operation,
modification or use of such software source code) in Hansen’s possession and under Hansen’s control for software necessary to operate Products within the Licensed Fields and using FOSSL Technology, or developed by Hansen pursuant to any
separate agreement with Philips and involving or relating to FOSSL Technology as imaged on a hard drive (collectively, “Source Code Materials”) with [***] (or, if [***] is not reasonably available, with another reputable software
escrow company to be mutually agreed by the Parties). 
 5.1 During such period, Hansen shall periodically update such Source
Code Materials with the latest versions thereof in Hansen’s possession and under Hansen’s control. 
 5.2 During such
period, the Source Code Materials shall be released to Philips in the event of the bankruptcy, liquidation or insolvency of Hansen or an assignment for the benefit of creditors by Hansen, or in the event that Philips requires access to the Source
Code Materials to comply with any governmental request. In addition, unless otherwise provided for separately in an agreement between Hansen and Philips, if Philips requests modifications to software licensed hereunder, including without limitation
bug fixes or additional functionality requested by Philips, and Hansen refuses to perform the development, maintenance or support of such software requested by Philips at Hansen’s standard rates or other reasonable and customary terms (it being
understood that Hansen has no obligation to do so), then Hansen shall cause the release of the applicable portion of the software to Philips. Philips shall protect the confidentiality of any source code made available to it hereunder with the same
degree of care it uses to protect its own source code and in any event no less than reasonable care. 
 5.3 All fees and
expenses payable to [***] (or such other escrow company, if any) for the establishment and maintenance of such escrow arrangement shall be borne and paid by Philips. 
 5.4 If Hansen has in Hansen’s possession and under Hansen’s control any source code within the Licensed Luna IP (e.g., after the release of such source code to Hansen pursuant to the 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 20 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
terms and conditions of Hansen’s escrow agreement with Luna, in the event of a default by Luna which causes such source code to be released from escrow), Hansen shall deposit such source
code into escrow for inclusion as part of the Source Code Materials hereunder. 
 6. Non-Competition. Except for Hansen Products within a
Buy Back Field for which Hansen obtains rights pursuant to Section 4, during the Term of the Agreement, Hansen shall not directly or indirectly develop, manufacture, distribute, sell or market any Hansen Products in the Vascular Non-Robotic Field,
the Endoluminal Non-Robotic Field, the Non-Robotic Medical Devices Field (including the Colonoscopy Non-Robotic Field), and the Orthopedics Field. To avoid doubt, the foregoing covenant shall not be read or interpreted to extend to the SDOF Medical
Robotics Field and the Medical Robotics Field. The covenant of this Section 6 shall not apply to any entity that acquires Hansen, by a Change of Control or otherwise, or any other Affiliate of Hansen following a Change of Control of Hansen or its
Affiliates, with respect to any intellectual property rights that such entity owned or otherwise controlled prior to the Change of Control or after such Change of Control (other than the FOSSL IP), or with respect to any activities already done by
that entity prior to the Change of Control or after such Change of Control (other than in connection with the FOSSL IP). 
 7. Hansen
Consulting Services. If the Parties mutually agree pursuant to a separate written agreement for consulting services related to the FOSSL Technology licensed hereunder, Hansen shall provide such consulting services to Philips on a time and
materials basis at Hansen’s then-current rates or such other rates as the Parties may agree in such written agreement. 
 8. Reports
Regarding Progress under Hansen-Luna Agreements and Delivery of FOSSL Technology. 
 8.1 During the Capture Period, Hansen
shall keep Philips reasonably informed on a reasonably frequent basis (at least [***]) of progress made by Hansen and, to the extent known to Hansen, by Luna under any agreement between Hansen and Luna for FOSSL Technology. This reporting shall be
done in writing to the attention of [***] 
 8.2 Hansen will notify Philips of, and will not object to a designee of Philips
attending, the CTO meetings specified in Section 2.3(f) of the Hansen-Luna Agreement; provided, however, that Philips’s right to attend each such meeting shall be subject to the execution of appropriate confidentiality agreements and
Luna’s prior written consent (in Luna’s sole discretion) with respect to each meeting. 
 8.3 Delivery of FOSSL
Technology. Within [***] of the Closing Date and on a [***] basis thereafter during the Capture Period for each party, to the extent in such Party’s possession and in the form of (1) copies of any then-existing reports, summaries,
memorandums, articles, invention disclosures, patents and patent applications, in each case (A) to the extent not already disclosed to the other Party and (B) in any event (i) excluding documents to the extent covered by
attorney-client privilege, (ii) excluding inventor notebooks, incomplete draft documents and mere email correspondence (but not excluding attached documents to the extent constituting the foregoing documents), and (iii) excluding any
information restricted from 
  
 [***] CONFIDENTIAL PORTIONS OF THIS
DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 21 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
disclosure to the other Party under third party confidentiality obligations, or (2) a document prepared by such Party that provides the substance of the responsive information that otherwise
would be provided pursuant to clause (1): (a) Hansen shall provide to Philips all FOSSL Technology meeting the foregoing that is described in Sections 1.26(b) and 1.28(b) to Philips, to the attention of [***] and (b) Philips shall provide
to Hansen all FOSSL Technology meeting the foregoing that is described in Section 1.40(b), to the attention of [***] or his/her successor based on Hansen’s notification. With each disclosure, the disclosing Party shall provide a written
summary identifying and generally describing the items disclosed. The disclosing Party shall reasonably respond to limited, brief follow-up inquiries from the receiving Party regarding the items disclosed by such Party under (1) and/or
(2) above for the purpose of confirming and complementing the sufficiency of the disclosures above. Disclosures required by the foregoing shall exclude software source code and related documentation and algorithms designed for the purpose of
incorporation into source code (without limiting the provisions of Section 5 of this Agreement). However, the foregoing obligations of this Section 8.3 shall not require the disclosing Party to generate any new documents, reports or other
materials that do not already exist (except to the extent the disclosing Party elects, in its sole discretion, to pursue (2) above instead of (1)) and shall not require the receiving Party to provide the disclosing Party with training with
respect to any inventions or Technology contained or described in any such disclosures. 
 8.3.1 The Parties will organize a
meeting between each Party’s CTO (or someone holding a comparable position) or representative(s) appointed by such CTO or other person holding a comparable position within 2 months of the Closing Date to discuss the shared FOSSL Technology
orally. After such meeting, the Parties shall agree as to which Party shall prepare a draft of written minutes for such meeting for approval by the other Party. 
 8.3.2 The Parties will meet at reasonable intervals agreed upon in writing by the Parties (and at least semi-annually during the Capture Period) to discuss the disclosed FOSSL Technology. 

8.3.3 Philips and Hansen will keep reasonable records of all written information received under this Article. 

8.3.4 Notwithstanding anything to the contrary set forth in this Agreement, this Section 8.3 shall terminate with respect to both
Parties upon the ending of the Capture Period with respect to either Party. 
 9. Prosecution, Maintenance, and Defense

 9.1 Purchased Hansen Patents (i.e., Hansen Group 1 Patents). Within the later of 60 days following the
Signing Date or five (5) days following the Closing Date, Hansen shall transfer all files relating to the prosecution and maintenance of the Purchased Hansen Patents to Philips. Hansen shall advise Philips of any filing deadlines due within 90
days of such transfer, and shall be responsible for maintaining the files and satisfying all filing obligations that are due prior to the transfer at Philips’ cost and expense. Upon such transfer, Philips shall have the sole 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 22 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
right and obligation, at Philips’ cost and expense, subject to Hansen’s rights under this Section 9.1, to file, prosecute and maintain the Purchased Hansen Patents. Philips shall
provide Hansen (through patent counsel designated as set forth in Section 9.4. of this Agreement) with copies of all material correspondence, applications and filings reasonably in advance of filing or sending them to the applicable patent
office for Hansen’s review and comment. Hansen shall have the right to monitor and comment on patent filings of Purchased Hansen Patents and the right to recommend claims directed to the Medical Robotics Field or SDOF Medical Robotics Field.
Philips shall reasonably consider any comments provided by Hansen (including with respect to filing in a particular jurisdiction), but Philips shall have the final authority with respect to such correspondence, applications and filings, except that
Philips shall not abandon or modify claims directed to the Medical Robotics Field or SDOF Medical Robotics Field without either Hansen’s prior written consent (e.g., given by Hansen’s review and approval of any draft of a submittal to a
patent office which is forwarded to Hansen by patent counsel designated as set forth in Section 9.4. of this Agreement) or allowing Hansen at least [***] from transmittal of any such draft to Hansen to review and approve or provide comments on
any such draft; however, with respect to claims within the Purchased Hansen Patents related to any and all activities and applications in the SDOF Medical Robotics Field or in the Medical Robotics Fields, if elections regarding obtaining patent term
restoration (i.e. to take into account a regulatory review period) are to be made and the Parties do not agree, Hansen shall have the right to make the election and Philips shall abide by such election. With respect to the Purchased Hansen Patents,
Philips shall provide Hansen with copies of all material correspondence, applications and filings filed with, sent to or received from the applicable patent office (following the receipt, filing or submission thereof, as the case may be). Hansen
shall have the right to request filing of divisional applications, continuations, or national stage entries for claim coverage in the SDOF Medical Robotics Field or in the Medical Robotics Field. In the event that Hansen requests any divisional
applications, continuations or national stage entries with respect to patent applications within the Purchased Hansen Patents, Hansen will pay for any prosecution of those applications and other costs and expenses associated therewith and have
rights to file, prosecute, maintain and enforce such patent rights as set forth in this Agreement. If Philips decides to cease prosecution or maintenance of any of the Purchased Hansen Patents, Philips shall first provide Hansen with written notice
of such decision within a reasonable period (but at least [***] if practicable) prior to any pending filing or maintenance fee deadline of which it is aware so Hansen may take, at Hansen’s sole cost and expense, whatever reasonable action may
be necessary with respect thereto. Hansen may, in its sole discretion, thereafter assume responsibility for such prosecution or maintenance at its sole cost and expense, and shall notify Philips in writing prior to assumption if it elects to assume
such responsibility. In such event, Philips and its Affiliates shall have a license under such Purchased Hansen Patent as if such Purchased Hansen Patent were a Licensed Hansen Patent, and shall assign (and hereby assigns, effective as of
Philips’ receipt of Hansen’s notice therefor) to Hansen such Purchased Hansen Patent, and thereafter Hansen shall provide Philips, upon Philips’s request, with copies of all material correspondence, applications, and other filings
with respect to any such Purchased Hansen Patents assumed by Hansen filed with, sent to or received from the applicable patent offices (following the receipt, filing or submission thereof, as the case may be). In the event Hansen so elects to assume
such responsibility for a given Purchased Hansen Patent, Philips shall reasonably cooperate at 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 23 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Hansen’s cost and expense. In the event such Purchased Hansen Patents become involved in any litigation, each Party shall have its respective rights set forth in Article 12 below.

 9.2 Licensed Luna Patents. With respect to the Licensed Luna Patents, licensed by Philips under the SPE-Philips
Agreement, Philips acknowledges that prosecution and maintenance of the Licensed Luna Patents is controlled by Luna pursuant to the terms of Section 5 of the Hansen-Luna Agreement. Hansen shall provide Philips with copies of all material
correspondence, applications and filings with respect to the Licensed Luna Patents filed with, sent to or received from the applicable patent office that Hansen receives from Luna. If Luna provides Hansen written notice of Luna’s decision to
cease prosecution or maintenance of any of the Licensed Luna Patents (in one or more countries), Hansen may thereafter assume responsibility for such prosecution or maintenance in accordance with the Hansen-Luna Agreement. In such event, the
following shall apply: Hansen shall first consult with Philips to determine whether Philips wishes to maintain an interest in the respective applications and filings. Hansen shall have the sole right to file, prosecute and maintain the Licensed Luna
Patents through outside counsel (Section 9.4). If Philips as well as Hansen is interested in maintaining an interest in the applications and filings, the Parties shall share [***] the costs of such filing, prosecution and maintenance, and Philips
shall reimburse Hansen for Philips’ share within sixty (60) days after the date of invoice therefor obtained from Hansen or directly from prosecution counsel. If only Philips (and not Hansen) is interested in maintaining an interest in the
applications and filings, Philips shall take over filing, prosecution and maintenance of the respective patent family(ies). 
 For Licensed Luna
Patents that are prosecuted/maintained by Hansen according to this article, Hansen shall provide Philips with copies of all material correspondence, applications and filings for the Licensed Luna Patents reasonably in advance of filing or sending
them to the applicable patent office for Philips’s review and comment and the rights and duties of the Parties with respect to such Licensed Luna Patents will be the same as set forth below in Section 9.3 with respect to Hansen Group 2
Patents, but Hansen shall have the final authority with respect thereto. In the event such Licensed Luna Patents become involved in any litigation, each Party shall have its respective rights set forth in Article 12 below. 

9.3 Hansen Group 2 Patents. For the avoidance of doubt, Hansen retains all rights to file, prosecute, maintain and, to the extent
set forth in Article 12 of this Agreement, enforce patent rights in and to the Licensed Hansen IP in Hansen’s discretion. Philips shall have the right to monitor and comment on patent filings of Hansen Group 2 Patents and the right to recommend
claims directed to the Licensed Field. Hansen shall reasonably consider any comments provided by Philips (including with respect to filing in a particular jurisdiction), but Hansen shall have the final authority with respect to such correspondence,
applications and filings, except that Hansen shall not abandon or modify claims directed to the Licensed Fields without either Philips’s prior written consent (e.g., given by Philips’s review and approval of any draft of a submittal to a
patent office which is forwarded to Philips by patent counsel designated as set forth in Section 9.4 of this Agreement) or allowing Philips at least [***] from transmittal of any such draft to Philips to review and approve or provide comments
on any such draft; however, with respect to 
  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 24 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
claims within the Hansen Group 2 Patents related to any and all activities and applications in the Licensed Fields, if elections regarding obtaining patent term restoration (i.e. to take into
account a regulatory review period) are to be made and the Parties do not agree, Philips shall have the right to make the election and Hansen shall abide by such election. In the event such Hansen Group 2 Patents become involved in any litigation,
each Party shall have its respective rights set forth in Article 12 below. 
 Philips shall have the right to request filing of divisional
applications, continuations, or national stage entries for claim coverage in the Licensed Fields In the event that Philips requests any divisional applications, continuations or national stage entries with respect to patent applications within the
Hansen Group 2 Patents, Philips will pay for any prosecution of those applications and other costs and expenses associated therewith and have rights to file, prosecute, maintain and enforce such patent rights as set forth in this Agreement.

 If Hansen decides to cease prosecution or maintenance of any of the Hansen Group 2 Patents, Hansen shall first provide Philips with written
notice of such decision within a reasonable period (but at least [***] if practicable) prior to any pending filing or maintenance fee deadline of which it is aware so Philips may take, at Philips’ sole cost and expense, whatever reasonable
action may be necessary with respect thereto. Philips may, in its sole discretion, thereafter assume responsibility for such prosecution or maintenance at its sole cost and expense, and shall notify Hansen in writing prior to assumption if it elects
to assume such responsibility. If Philips decides to cease prosecution or maintenance of any divisional applications, continuations or national stage entries with respect to patent applications within the Hansen Group 2 Patents, Philips shall first
provide Hansen with written notice of such decision within a reasonable period (but at least [***] if practicable) prior to any pending filing or maintenance fee deadline of which it is aware so Hansen may take, at Hansen’s sole cost and
expense, whatever reasonable action may be necessary with respect thereto. Hansen may, in its sole discretion, thereafter assume responsibility for such prosecution or maintenance at its sole cost and expense, and shall notify Philips in writing
prior to assumption if it elects to assume such responsibility. In such event, Philips and its Affiliates shall continue to have a license under such Hansen Group 2 Patents as if such Purchased Hansen Patent were a Licensed Hansen Patent. Regardless
of the foregoing, ownership of the Hansen Group 2 Patents shall remain with Hansen. 
 9.4 Prosecution Counsel. Philips
will select counsel for filing and prosecution of such patent applications (including continuations, divisional applications and non-U.S. national stage filings) as are paid for in whole by Philips as set forth in this Agreement, including, the
Purchased Hansen Patents, any Licensed Luna Patents for which prosecution and maintenance are assumed by Hansen but paid for in whole by Philips and for which responsibility can be transferred from Luna as set forth in the Hansen-Luna Agreement or
other agreement between Luna and Hansen, and any Hansen Group 2 Patents where prosecution and maintenance cost and expense are paid for in whole by Philips (i.e., divisional applications, continuations, or national stage entries filed at the request
of Philips for claim coverage in the Licensed Fields and paid for by Philips). Hansen agrees to use reasonable efforts to retain, with respect to its obligations under this Section 9.4, the same counsel for any patent prosecution or maintenance
which is 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED
AND SEPARATELY FILED WITH THE COMMISSION. 

  
 25 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
continued or later initiated by Hansen, as the counsel Philips uses, with respect to patent applications claiming priority to the Purchased Hansen Patents. The Parties shall use reasonable
efforts to assure each patent family is prosecuted by the same counsel and consistent with the efforts taken for other applications and patents governed by this Section 9, notwithstanding the fact that the patent family may include divisional
applications requested by Philips. Philips will not be responsible for filing, prosecution, issue, maintenance or other patent costs and expenses related to any Licensed Hansen Patents or Licensed Luna Patent unless set forth herein or authorized in
advance, in writing, by Philips’ patent portfolio manager. 
 9.5 Prosecution and Maintenance of Licensed Luna
Patents. To the fullest extent such rights have been granted to Hansen under the Hansen-Luna Agreement or other agreements between Hansen and Luna, Philips shall have and Hansen agrees to exercise on Philips’ behalf, in accordance with
Section 9.2, the right to monitor and comment on patent filings of Licensed Luna Patents, the right to recommend or require (to the extent permitted under the Hansen-Luna Agreement) country selection for Licensed Luna Patents, particularly with
regard to filing and prosecution of non-U.S. counterparts. Subject to Section 9.2, Hansen shall reasonably consider any comments provided by Philips (including with respect to filing in a particular jurisdiction), and use reasonable efforts to
resolve any inconsistencies between Hansen and Philips’ positions with regard to the prosecution, and use reasonable efforts to incorporate Philips’ comments consistent with Hansen’s positions in such Luna correspondence, applications
and filings. Notwithstanding anything to the contrary in this Section 9.5 and in Section 9.2, Philips’ right and ability to monitor and comment on any Licensed Luna Patents under this Section 9.5 and Section 9.2 shall be subject to
Luna’s consent to the extent not already authorized under the Hansen-Luna Agreement. 
 10. Representations, Warranties and
Covenants; Conditions to Closing 
 10.1 Hansen-Luna Agreement. Upon the reasonable request of Philips,
following the Closing, Hansen shall use commercially reasonable efforts to enforce the representations and warranties and covenants received by Hansen in the Hansen-Luna Agreement for which Philips presents reasonable evidence of a breach thereof in
such notice and which breach would have a material and adverse effect on Philips’ rights hereunder; provided, however, that Hansen shall not be obligated to enforce such representations and warranties and covenants to the extent Hansen
reasonably determines it has legitimate concerns that such enforcement will have a significant adverse impact on the other benefits and rights Hansen receives from Luna under the Hansen-Luna Agreement and/or the Development and Supply Agreement.

 10.2 Hansen represents and warrants that, as of the Signing Date and the Closing Date: 

10.2.1 Prior to the assignment to Philips hereunder, Hansen is the sole owner of the Purchased Hansen Patents and Hansen has good and
marketable title thereto. None of the Purchased Hansen Patents are subject to any lien, charge, security interest or other encumbrance, except as described in Section 2.3. 

  
 26 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 10.2.2 Hansen has the full and unrestricted right and necessary power and authority to
execute and deliver this Agreement, grant the rights granted herein and consummate the transactions contemplated hereby. 

10.2.3 Hansen is in compliance in all material respects with the Hansen-Luna Agreement, Development and Supply Agreement, and
Hansen-Intuitive Cross License Agreement (collectively, the “Material Contracts”). Hansen is not and to Hansen’s knowledge the other parties to the Material Contracts are not in material breach or default under the terms of any
Material Contract, which default would have an adverse effect on Philips’ rights hereunder, and to Hansen’s knowledge there exists no event, condition or occurrence which would constitute such a breach or default by Hansen or such parties,
nor has Hansen received any notice of any breach or default or alleged breach of default under any Material Contract. None of the Material Contracts are subject to any Third Party lien, charge, security interest or other encumbrance except as may be
set forth in the terms and conditions of the Material Contracts. Hansen has not waived or allowed to lapse any of its rights under any of the Material Contracts, and no such rights have lapsed or otherwise expired or been terminated that would have
an adverse effect on the rights granted to Philips and its Affiliates hereunder 
 10.2.4 The execution and delivery by Hansen
of this Agreement or any other instrument or document required by this Agreement do not, and the performance of this Agreement, including, without limitation, the granting of licenses granted hereunder, will not, (a) conflict with or violate
the organizational documents of Hansen, (b) conflict with or violate any law, order or regulation applicable to Hansen, or (c) result in any breach or violation of or constitute a material default under, or give to others any rights of
termination, amendment, acceleration or cancellation of, or result in the creation of a lien, charge, security interest or encumbrance in favour of any Third Party on any of the property or assets of Hansen relating to the Agreement. 

10.2.5 Hansen has not granted any right, license, or interest in, to or under the FOSSL IP inconsistent with the rights and licenses
granted to Philips in this Agreement. 
 10.2.6 Where Hansen has granted an exclusive license herein, Hansen represents and
warrants that it has not granted any prior licenses under the FOSSL IP, and will not continue to practice within those fields except as expressly set forth herein. 
 10.2.7 To Hansen’s knowledge, no opposition or invalidity proceedings are pending in relation to any of the Licensed Patents or Purchased Hansen Patents, and no such proceedings have been threatened
in writing 
 10.2.8 To Hansen’s knowledge, there is no intellectual property or conduct that it believes could reasonably
render the Licensed Patents invalid or unenforceable. 
 10.2.9 Hansen is not actually aware of any issued patents or pending
patent applications owned by Third Parties that would be infringed by Hansen’s and/or Philips’ practice of the FOSSL IP as such FOSSL IP exists by itself as of the Signing Date (i.e., excluding any modifications, improvements or
alterations or incorporation of other technology). This 

  
 27 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
representation is not intended to guarantee that no component of any commercial product of Philips, its Affiliates or its licensees would infringe or otherwise violate patents owned by a Third
Party. 
 10.2.10 To Hansen’s knowledge, Luna or any of the patent holders of the FOSSL IP are not due any consideration
from Philips as a result of this Agreement. 
 10.2.11 With the exception of the consent listed on Exhibit I, no additional
consents of, or notice to, any third party is required for Hansen to execute and deliver this Agreement or under any Material Contract, and neither the enforceability nor any of the terms or provisions of any Material Contract will be amended or
terminated by, the execution, delivery and performance of this Agreement, or the transactions contemplated hereby. 
 10.2.12
Hansen has disclosed all of Hansen’s patents and patent applications covering FOSSL Technology to Philips. To the extent any additional Hansen patents and patent applications covering FOSSL Technology exist that had not been previously
disclosed, the Parties will discuss whether such patents and patent applications should be added to Hansen Group 2 Patents or the Hansen Group 3 Patents within reasonable time after the patent or patent application has come to the attention of the
Parties. 
 10.2.13 Hansen (i) has sufficient capital to carry on its business, (ii) is able to pay its debts as they
mature and (iii) is and, after giving effect to the transactions contemplated hereby, will be, solvent, and the value of its assets, at a fair valuation, is and, after giving effect to the transactions contemplated hereby, will be, greater than
all of its debts. Hansen has not (i) made a general assignment for the benefit of creditors, (ii) filed any voluntary petition in bankruptcy or suffered the filing of an involuntary petition by any creditor, (iii) suffered the
appointment of a receiver to take possession of all or any portion of its assets, (iv) suffered the attachment or judicial seizure of all or any portion of its assets, (v) admitted in writing its inability to pay its debts as they come due
nor (vi) made an offer of settlement, extension or composition to its creditors generally. 
 10.2.14 The terms and
provisions of this Agreement were negotiated at arm’s length and are fair, reasonable and consistent with existing market conditions. Hansen has undertaken discussions with other potential purchasers/licensees of the FOSSL IP and, based on
those discussions and Hansen’s own knowledge of market conditions, believes that the terms provided for in this Agreement, including price, represent in their totality the most favorable terms available to Hansen. The transactions contemplated
by this Agreement are not being entered into by Hansen with the intention of hindering, delaying or defrauding any of Hansen’s current or future creditors. 
 10.3 Hansen Covenants: 
 10.3.1 Hansen will not amend or modify the Material
Contracts in a way that would be inconsistent with any term of this Agreement. 

  
 28 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 10.3.2 Hansen will keep in full force and effect the Material Contracts (other than the
Hansen-Luna Agreement after such agreement is assigned to SPE), materially comply with Hansen’s obligations under the Material Contracts, and not reduce any of its rights under such agreement in a way that would be inconsistent with any term of
this Agreement. 
 10.3.3 Between the Closing Date and the actual transfer of the files related to the Purchased Hansen patents,
Hansen shall use its best efforts to preserve intact the Purchased Hansen Patents and shall not, directly or indirectly, sell, transfer, lease, license, sublicense, mortgage, pledge, encumber, grant or otherwise dispose of or grant a lien on any
Purchased Hansen Patents, or amend or modify any existing agreements with respect to any Purchased Hansen Patents. 
 10.3.4
Upon the terms and subject to the conditions set forth in this Agreement, each Party hereto shall use commercially reasonable efforts to take, or cause to be taken, all actions, and do, or cause to be done, and to assist and cooperate with the other
Party in doing, all things reasonably necessary, proper or advisable to consummate the transactions contemplated hereby. 
 10.4
Closing Conditions. The obligation of Philips to effect the Closing shall be subject to the satisfaction at or prior to the Closing of the following conditions, unless waived in writing by Philips: 

10.4.1 Representations and Warranties. Each of the representations and warranties of Hansen set forth in this Agreement shall be
true and correct in all material respects as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date. Each of the representations and warranties of Hansen set forth in this Agreement that is qualified by
materiality shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date and each of the other representations and warranties of Hansen set forth in this Agreement
shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date. 
 10.4.2 Agreements and Covenants. Hansen shall have performed or complied in all material respects with each obligation, agreement and covenant to be performed or complied with by it under this
Agreement on or prior to the Closing Date. 
 10.4.3 No Injunctions or Restraints; Illegality. No temporary restraining
order, preliminary or permanent injunction or other order (whether temporary, preliminary or permanent) issued by any court of competent jurisdiction or other legal restraint or prohibition shall be in effect which restrains, enjoins or otherwise
prohibits the consummation of the transactions contemplated hereby, nor shall any proceeding brought by any person seeking any of the foregoing be pending, and there shall not be any action taken, or any law or order enacted, entered, enforced or
deemed applicable to transactions contemplated hereby, which restrains, enjoins or otherwise prohibits the consummation of the transactions contemplated. 

  
 29 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 10.4.4 Officer’s Certificate. Hansen shall have delivered to Philips a
certificate of Hansen executed by an executive officer of Hansen, dated as of the Closing Date, in form and substance reasonably satisfactory to Philips, certifying that the conditions set forth in Sections 10.4.1, 10.4.2 and 10.4.3 have been
satisfied. 
 10.4.5 Patent Assignment. Hansen shall have executed and delivered to Philips the patent assignment in the
form attached as Annex 2 pursuant to which Hansen will transfer and assign to Philips the Purchased Hansen Patents. 
 10.4.6
Sublicense Agreement. SPE shall have executed and delivered to Philips the SPE-Philips Agreement and SPE shall have complied with all obligations to be complied with by SPE on or prior to the Closing Date under the SPE-Philips Agreement on or
prior to the Closing Date. 
 10.4.7 JDA Amendment. The Extended Joint Development Agreement between Philips and Hansen
dated as of November 15, 2009, as amended by Amendment No. 1 to Extended Joint Development Agreement dated as of the date hereof shall have not been revoked and shall be in full force and effect as of the Closing Date. 

10.4.8 Legal Opinions. Morrison and Foerster LLP, counsel to Hansen and SPE, shall have delivered to Philips a customary
“non-consolidation” legal opinion and a “true sale” legal opinion and legal opinions as to enforceability, due authorization and no conflict with Material Contracts. 

10.4.9 SVB Consent. SPE shall have received consent from Silicon Valley Bank in the form attached hereto as Exhibit I. 

10.5 Conditions to Closing by Hansen. The obligation of Hansen to effect the Closing shall be subject to the reasonable
satisfaction at or prior to the Closing of the following conditions, unless waived in writing by Philips: 
 10.5.1
Representations and Warranties. Each of the representations and warranties of Philips set forth in this Agreement shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date as though made on
and as of the Closing Date. 
 10.5.2 Agreements and Covenants. Philips shall have performed or complied in all material
respects with each obligation, agreement and covenant to be performed or complied with by it on or prior to the Closing Date under this Agreement on or prior to the Closing Date. 

10.5.3 Officer’s Certificate. Philips shall have delivered to Hansen a certificate of Philips executed by an officer of
Philips, dated as of the Closing Date, in form and substance reasonably satisfactory to Hansen, certifying that the conditions set forth in Sections 10.5.1 and 10.5.2 have been satisfied. 

  
 30 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 10.5.4 Initial Payments. Philips shall have made the payments set forth in
Section 3.2 of this Agreement and Section 3.1 of the SPE-Philips Agreement 
 10.6 Disclaimer. EXCEPT AS
EXPRESSLY SET FORTH IN THIS ARTICLE 10, ANY AND ALL FOSSL IP, CONFIDENTIAL INFORMATION, TECHNOLOGY AND INTELLECTUAL PROPERTY (AND ANYTHING ELSE) LICENSED, ASSIGNED, DISCLOSED OR PROVIDED BY EITHER PARTY TO THE OTHER PARTY IN CONNECTION WITH THIS
AGREEMENT SHALL BE ON AN “AS IS” BASIS, WITHOUT ANY REPRESENTATION OR WARRANTY WHATSOEVER. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 10, ANY AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT
NOT LIMITED TO ANY AND ALL WARRANTIES RELATED TO MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ABSENCE OF ERRORS AND/OR BUGS, ACCURACY OR COMPLETENESS OF RESULTS, VALIDITY, SCOPE OR NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHT, ARE
EXPRESSLY DISCLAIMED. 
 10.7 Legal Opinion Expenses. Within sixty (60) days of receipt of an invoice therefor, Philips
shall pay Hansen [***] of Hansen’s [***] incurred in preparing and delivering the [***], provided in no event shall such reimbursement exceed [***] 
 11. Indemnification 
 11.1 By Philips. From and after the
Closing, Philips shall indemnify, defend and hold harmless Hansen, its Affiliates and their respective directors, officers, agents and employees (the “Hansen Indemnitees”) from and against any and all claims, damages, liabilities,
costs, expenses or loss, including reasonable legal expenses and reasonable attorneys’ fees (“Losses”) resulting from or arising out of suits, claims, proceedings or causes of action brought by a Third Party (each, a
“Third Party Claim”) against any one or more of the Hansen Indemnitees, arising from this Agreement (i) to the extent based on a proven defect of a FOSSL System sold by Philips or its present or future Affiliates or
(ii) for bodily injury including pain and suffering, death and tangible property damage arising from this Agreement to the extent based on: (a) the breach by Philips of this Agreement; (b) the negligence or willful misconduct of
Philips or its Affiliates, (c) the violation of applicable law by Philips Medical Systems or its Affiliates; except to the extent for which Hansen is required to indemnify, defend and hold harmless Philips pursuant to Section 11.2; and all
limited to the extent the claims are related to this Agreement and connected to FOSSL Technology. 
 11.2 By
Hansen. From and after the Closing, Hansen shall indemnify, defend and hold harmless Philips, its Affiliates and their respective directors, officers, agents and employees (the “Philips Indemnitees”) from and against
any and all Losses resulting from or arising out of a Third Party Claim against any one or more of the Philips Indemnitees, to the extent based on: (a) the breach by Hansen of this Agreement, including without limitation a
representation or warranty or covenant contained in Article 10 or Section 20.5; (b) the violation of applicable law by Hansen or its Affiliates; (c) the negligence or willful misconduct of Hansen or its Affiliates 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 31 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
or (d) a claim for which Hansen is indemnified by Luna under the Development and Supply Agreement, to the extent Hansen is actually indemnified thereunder; except to the extent for which
Philips is required to indemnify, defend and hold harmless Hansen pursuant to Section 11.1; and all limited to the extent the claims are related to this Agreement and connected to FOSSL Technology. 

11.3 Procedures. The Party requesting indemnification (“Indemnitee”) shall give prompt written notice to
the Party required to provide indemnification (“Indemnifying Party”) of any Third Party Claim, with respect to which indemnification may be required under this Section 11, provided, however, that failure to give notice shall not
impair the obligation of the Indemnifying Party to provide indemnification hereunder except if and to the extent that failure materially impairs the ability of the Indemnifying Party successfully to defend the Third Party Claim. The Indemnifying
Party shall be entitled to assume the defense and control of any Third Party Claim at its own cost and expense, but the Indemnitees shall have the right to be represented by its own counsel at its own cost in such matters. The Indemnitees shall
provide all reasonable assistance to the Indemnifying Party, at the Indemnifying Party’s expense, in connection with the defense of any Third Party Claim hereunder. Neither Party shall settle or dispose of any Third Party Claim in any manner
which would adversely impact the rights or interests of the other Party under this Agreement without the other Party’s prior written consent, without limiting the application of the royalty-stacking provisions of Section 3.4. 

11.4 Notwithstanding anything in the foregoing, a Party shall not be required to indemnify the other Party for any liability such other
Party incurs arising from some act or omission for which such other Party is responsible under applicable law. 
 12. Enforcement of Licensed
Patents and Purchased Hansen Patents 
 12.1 Notification. Each Party shall promptly notify the other Party in
writing if the notifying Party reasonably believes that any Purchased Hansen Patent or any of the Licensed Patents is being threatened, being infringed or has been infringed by a Third Party. Neither Party, however, shall seek to enforce, without
written consent of the other Party, any claims covering FOSSL Technology within the Purchased Hansen Patents, the Licensed Luna Patents or the Hansen Group 2 Patents [***] (as reasonably determined in good faith by the Party seeking to enforce the
patent rights) or to obtain an injunction against a potential competitor [***] except to the extent required to comply with Hansen’s obligations under the Hansen-Luna Agreement, Development and Supply Agreement or [***] To be clear, the
foregoing shall not apply to Hansen’s right to enforce claims covering non-FOSSL Technology within the Hansen Group 2 Patents. 
 12.2 Enforcement within the Vascular Non-Robotic Field, the Endoluminal Non-Robotic Field or the Orthopedics Field. With respect to any infringement (or allegation of infringement) of any of
the Licensed Luna Patents or the Hansen Group 2 Patents within the Vascular Non-Robotic Field, the Endoluminal Non-Robotic Field or the Orthopedics Field (such infringement, “Exclusive License Infringement”), [***] shall have the
[***] to institute enforcement actions against any person or entity engaged in perceived Exclusive License 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 32 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Infringement at its own cost and expense. [***] shall keep [***] reasonably informed with respect to the status of any such enforcement action. Recoveries related to Exclusive License
Infringement shall be as set forth in Section 12.7. With respect to any infringement (or allegation of infringement) of any of the Licensed Luna Patents or the Hansen Group 2 Patents other than Exclusive License Infringement or any other Licensed
Hansen IP (including without limitation the Hansen Group 3 Patents), as between Hansen and Philips, [***] shall have the [***] to institute enforcement actions against any person or entity engaged in such infringement, in each case at its own cost
and expense. Hansen shall retain all recoveries related thereto. [***] shall keep [***] reasonably informed with respect to the status of any such enforcement action. If any litigation or proceedings before a patent office involves [***] of any of
the [***] shall consult with [***] and provide [***] for [***] to [***], provided that [***], Hansen and Philips will cooperate so as not to [***], and in no event will [***] be required to disclose information that would [***] and will [***]
provided by [***] regarding the [***] by a Third Party regarding any of the [***] 
 12.3 Enforcement of Purchased Hansen
Patents. With respect to any infringement (or allegation of infringement) of (a) any divisional or continuation application of U.S. Patent Application No. [***], and (b) U.S. Patent Application No. [***] and U.S. Patent Application No.
[***], in the [***] (such infringement, “Grantback License Infringement”), Hansen shall have the first right (but not the obligation) to institute enforcement actions against any person or entity engaged in perceived Grantback
License Infringement at its own cost and expense, and Hansen shall retain all recoveries related thereto. Hansen shall have the same right, but not the obligation, to enforce U.S. Patent Application No. [***] and U.S. Patent Application No. [***].

 12.4 If Hansen does not bring an action to prevent or abate the Grantback License Infringement within [***] after
notification thereof, then Philips shall have the right (but not the obligation) to institute an enforcement action against any person or entity engaged in perceived Grantback License Infringement at its own cost and expense. 

12.5 Cooperation. The Party instituting an enforcement action pursuant to Section 12.2 or Section 12.3 (“Enforcing
Party”) shall keep the other Party (“Non-Enforcing Party”) reasonably apprised of all developments in such enforcement actions and shall consult with the Non-Enforcing Party regarding such enforcement activities. The
Non-Enforcing Party shall, at the Enforcing Party’s cost and expense, reasonably cooperate with the Enforcing Party and provide all reasonable assistance in connection with any such litigation, including without limitation agreeing to be named
as a party or in the case of Hansen, causing Luna to be named to such action or having such action brought in the Non-Enforcing Party’s name by the Enforcing Party if and to the extent required for the Enforcing Party to have the legal right to
initiate such an enforcement action. 
 12.6 Settlement. The Enforcing Party shall have the right to settle the
dispute provided, however, no settlement, consent judgment or other voluntary final disposition of the action that involves an admission of the Non-Enforcing Party’s liability or wrongdoing, requires the Non-Enforcing Party to take or refrain
from taking any action or incur any payment 
  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 33 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
obligations or other liabilities or otherwise binds the Non-Enforcing Party or that involves an admission of the invalidity or unenforceability of the Licensed Hansen IP or Licensed Luna IP or
other IP of the Non-Enforcing Party or that could reasonably be likely to restrict the Non-Enforcing Party from conducting its business, may be entered into without the express written consent of the Non-Enforcing Party, which consent shall not be
unreasonably withheld. To the extent Hansen incurs any indemnification liability under Section 5.2(e) of the Hansen-Luna Agreement on account of any Philips enforcement action hereunder, Philips shall indemnify and hold harmless Hansen with
respect thereto. 
 12.7 Allocation of Proceeds. Recoveries from enforcement actions brought under Section 12.2 for
Exclusive License Infringement shall be allocated first to the reimbursement of any costs and expenses incurred by Philips to the extent not previously reimbursed, and then to the reimbursement of any costs and expenses incurred by Hansen, and then
with respect to any remaining amounts [***] . 
 13. Term and Termination: 

13.1 Term. This Agreement shall be effective as of the Closing Date, and shall remain in force until the expiration date of the
last to expire Licensed Patent (the “Term”), unless terminated earlier pursuant to Section 13.2. 
 13.2
Termination. 
 13.2.1 Unless agreed to otherwise in writing in advance by the Parties, the termination of the SPE-Philips
Agreement by a party to such agreement for a particular reason shall automatically and without any action required by the Parties terminate this Agreement as if for the same reason and any elections made with respect to termination by the
terminating party under the SPE-Philips Agreement shall be deemed elections made with respect to termination of this Agreement, mutatis mutandis and with references to SPE interpreted as references to Hansen. By way of non-limiting example,
if Philips terminates the SPE-Philips Agreement pursuant to Section 9.2.1 of the SPE-Philips Agreement and makes the election specified in Section 9.2.2(ii)(1) of the SPE-Philips Agreement, Philips shall be deemed to have terminated this
Agreement pursuant to Section 13.2.1 and to have made the election specified in Section 13.2.2(ii)(1). Without limiting the foregoing, this Agreement (and with respect to Section 13.2.1(iii), any part of this Agreement relating to the
subject matter acquired by the non-practicing entity) may be terminated: 
 (i) by a Party in the event of a material breach of
the Agreement by the other Party which has not been cured within 90 days of notice by the non-breaching Party. 
 (ii) by
Philips, in the event Hansen merges with, is purchased by, or is otherwise acquired by a competitor of the relevant business in Philips or if a majority of the Hansen shares are acquired by a competitor of the relevant business in Philips.

  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND
SEPARATELY FILED WITH THE COMMISSION. 

  
 34 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 (iii) by Philips, in the event Hansen or the Licensed Hansen IP is purchased or
otherwise acquired by a non-practicing entity (e.g., a company that acquires patent rights solely for purposes of enforcing rights, and not for making using or selling any products or services). If Philips chooses not to terminate this Agreement
pursuant to this Section 13.2.1(iii), Article 12 shall not apply to the non-practicing entity, but rather Philips shall control all enforcement of the Purchased Hansen Patents and the Hansen Group 2 Patents in all respects, and shall keep all
recovery from any such enforcement. 
 Such rights of termination shall not be exclusive of any other surviving provisions,
remedy or means of redress to which the non-defaulting Party may be lawfully entitled and all such remedies shall be cumulative. 
 13.2.2 In addition, the following shall apply: 
 (i) Termination of this
Agreement by Hansen for any reason other than failure of Philips to make the full payments pursuant to Section 3.2 of this Agreement and Section 3.1 of the SPE-Philips Agreement shall not result in the termination of any of the licenses
granted hereunder or reversal of any of the ownership transfers effectuated hereunder, but shall entitle Hansen to bring a claim for money damages arising from Philips’ uncured material breach. 

(ii) In case of termination of this Agreement by Philips, Philips shall have the right to elect by written notice either (1) to
terminate all licenses granted by the Parties to each other hereunder, effective from the termination date, and to return all purchased Intellectual Property, Technology, items and licensed rights and materials hereunder to Hansen (and such licenses
shall terminate and Philips shall comply with its obligations to return the foregoing), with reservation of the right to claim damages arising from the uncured material breach or (2) to maintain all such licenses and transfers of ownership
interests in full force and effect subject to the payment obligations in Section 3.3 and Section 3.5, but with reservation of its right to damages arising from the uncured material breach. 

(iii) Termination shall not release either Party from any payment or other obligation that has accrued as of the effective date of the
termination. Without limiting the generality of the foregoing, each Party shall pay the other, within thirty (30) days after such termination, amounts equal to all reimbursable expenses, patent royalties, milestone payments and other payments
of whatever nature which are then owed to such Party hereunder. 
 (iv) Upon termination of this Agreement
by Philips pursuant to Section 13.2.1, if Philips makes the election specified in 13.2.2(ii)(1): (1) all licenses granted by Hansen to Philips pursuant to Section 2 shall automatically terminate (2) Philips may, if it deems
appropriate as contributing to the mitigation of damages, promptly prepare, execute, deliver, transfer and assign to Hansen all regulatory filings and marketing authorizations covering FOSSL Systems (and related Products) for the Licensed Fields,
including any 

  
 35 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
rights of reference necessary or appropriate in connection therewith; (3) Philips may, if it deems appropriate as contributing to the mitigation of damages, transfer to Hansen all data,
materials, results and other information generated by or for Philips in support of regulatory approval for FOSSL Systems (and related Products) for the Licensed Fields prior to the date of such termination; (4) Philips shall cease using and,
within thirty (30) days after termination, return (and cause its Affiliates and its and their licensees and sublicensees to cease using and to return) to Hansen all Hansen Confidential Information provided to Philips by Hansen pursuant to this
Agreement and marked as such; (5) Philips may, if it deems appropriate as contributing to the mitigation of damages, grant to Hansen a nonexclusive, irrevocable, perpetual license (with the right to sublicense through one or multiple tiers) to
any and all FOSSL Technology (and any IP therein or thereto) owned or controlled by Philips as of the effective date of such termination and developed, made, created, conceived, reduced to practice (in whole or in part) by or for Philips or its
Affiliates or its or their licensees or sublicensees in connection with the exercise of the licenses granted to Philips and its Affiliates hereunder; (6) without limiting the license granted by Philips under Section 2.2.2, Philips may, if it
deems appropriate as contributing to the mitigation of damages, grant to Hansen a nonexclusive, irrevocable, perpetual license (with the right to sublicense through one or multiple tiers) under the Purchased Hansen Patents in the Vascular
Non-Robotic Field, the Endoluminal Non-Robotic Field, the Non-Robotic Medical Devices Field (including the Colonoscopy Non-Robotic Field), and the Orthopedics Field; and (7) Philips automatically shall be deemed to have assigned to Hansen all
Naked Licenses and Naked Sublicenses (or other sublicenses of FOSSL IP hereunder) existing as of the effective date of termination unless Hansen declines such assignment within thirty (30) days of termination. 

(v) Without limiting the foregoing, upon termination by Philips pursuant to Section 13.2.1(ii), the following provisions will
terminate immediately upon payment by Philips to Hansen or its acquirer of USD one million ($1,000,000): Section 3.3 (Product Payments, reporting requirements, and certain sections related thereto, e.g., 3.4, 3.6, 3.14 and 3.15); and any Naked
Sublicenses (under Section 3.5) granted after the transaction contemplated by Section 13.2.1(ii). For the avoidance of doubt, all Naked Sublicenses existing prior to the transaction contemplated in Section 13.2.1(ii), shall remain in
force. 
 13.2.3 Certain Effects for Termination by Hansen. Upon termination of this Agreement by Hansen pursuant to
Section 13.2 for failure of Philips to make the full payments mentioned in Section 3.2 of this Agreement and Section 3.1 of the SPE-Philips Agreement (i) Philips acknowledges that no licenses shall have been granted by Hansen pursuant
to Section 2; (ii) Philips shall assign (and hereby assigns, effective as of the effective date of such termination) to Hansen the Purchased Hansen Patents, and Philips shall transfer all files relating to the prosecution and maintenance
of the Purchased Hansen Patents to Hansen; and (iii) Philips shall cease using and, within thirty (30) days after termination, return (and cause its Affiliates and its and their licensees and sublicensees to cease using and to return) to
Hansen all Hansen Confidential Information marked as such, provided to Philips by Hansen pursuant to this Agreement. 

  
 36 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 13.3 Survival. Provided the Closing has occurred, 

13.3.1 The following Sections shall survive the termination or the expiration of this Agreement for any reason and in all circumstances:
2.2.2 (except for Philips’ retained right to research, develop, make, have made, use, have used, import, sell, have sold and otherwise commercialize and exploit Products in each case solely within SDOF Medical Robotics Field), 2.6, 2.7, 3.7,
3.9, 3.10, 3.11, 3.12, 3.13, 4, 10.6, 11, and 13 through 21. 
 13.3.2 In addition to the Sections set forth in Section 13.3.1,
the following Sections shall survive the termination of this Agreement (a) in the event of termination of this Agreement by Hansen for any other cause than failure of Philips to make the full payment mentioned in Section 3.2 or payments
due under Section 3.3 and Section 3.5 or (b) in the event of termination of this Agreement by Philips and if Philips makes the election specified in Section 13.2.2(ii)(1): 3.3, 3.4, 3.5, 3.6, 3.8, 3.14, 3.15, 5, 6, 8, 9 and 12. Further, if
the licenses granted by Hansen to Philips expressly survive termination of this Agreement as provided for above, then, for the avoidance of doubt, Sections 2.3, 2.4 and 2.5 shall also survive together with such rights and licenses. 

14. Bankruptcy: Notwithstanding anything to the contrary in this Agreement, the Parties hereto acknowledge and agree that all rights, privileges,
releases, non-assertions, immunities and licenses granted under or pursuant to this Agreement by Hansen to Philips and its Affiliates are, and are intended to be, and shall be deemed to be, for purposes of Section 365(n) of title 11 of the
United States Code, (as may be amended from time to time, “the Bankruptcy Code”), licenses of rights to intellectual property (including without limitation “intellectual property” as defined under Section 101(35A) of the
Bankruptcy Code) and: (a) all reports, drawings, samples, prototypes and other books and records and embodiments of the intellectual property shall be deemed “embodiments” of the intellectual property protected by Section 365 of
the Bankruptcy Code hereunder; and (b) any escrow agreements established pursuant to this agreement shall be an “agreement supplementary” to this Agreement for the purposes of Section 365(n) of the Bankruptcy Code. All of the
rights of Philips and its Affiliates under this Agreement shall be deemed to exist immediately before the occurrence of any bankruptcy proceeding in which Hansen is a debtor. The Parties hereto acknowledge and agree that Philips and its Affiliates,
as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the Bankruptcy Code or equivalent law, statute, treaty or legislation in any other jurisdiction including, but not limited
to, those rights and remedies under Section 365(n) of the Bankruptcy Code. Without limiting the generality of the foregoing, Hansen further agrees that, in the event that any proceeding shall be instituted by or against Hansen seeking to
adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief or composition of Hansen or its debts under any law relating to bankruptcy, insolvency, or reorganization or
relief of debtors, or seeking an entry of an order for relief or the appointment of a receiver, trustee or other similar official for Hansen or any substantial part of its property or if Hansen shall take any action to authorize any of the foregoing
actions (collectively, an “Insolvency Proceeding”), Philips and its Affiliates shall retain all rights, licenses, privileges, releases, non-assertions and immunities granted under or


  
 37 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
pursuant to this Agreement and their rights to enforce these rights under this Agreement. Without limiting the foregoing, to the maximum extent permitted by law, Philips and its Affiliates
shall not be affected by the rejection of this Agreement in any such Insolvency Proceeding (a “Rejection”) and Philips and its Affiliates shall retain all rights and remedies as provided under Section 365(n) of the Bankruptcy
Code. Upon any Rejection, Hansen and/or any trustee shall be required to turn over the intellectual property subject to this Agreement to Philips upon written request made by Philips to Hansen and/or the trustee. Philips shall under no
circumstances be required to terminate this Agreement after a Rejection in order to enjoy or acquire any of its rights under this Agreement; provided, however, upon any such Rejection Philips shall have the automatic right to terminate this
Agreement. In the event that this Agreement is subject to a Rejection any continuing payments required by Philips hereunder shall be equitably adjusted to reflect the loss of any services or other rights of Phillips and its Affiliates or obligations
of Hansen or its Affiliates that are terminated as a result of any such Rejection. Notwithstanding anything in this Agreement to the contrary, in the event that Hansen files for relief or protection under the Bankruptcy Code, or there is otherwise
an Insolvency Proceeding by or against Hansen, Hansen acknowledges and agrees that each and all of the rights, licenses, privileges, non-assertions and immunities granted to Philips under this Agreement are not assumable by Hansen (or a trustee) and
are not assignable to a Third Party. Upon any such Insolvency Proceeding by or against Hansen, Philips shall be deemed to have made a request for enforcement of all of its rights and licenses pursuant to Section 365(n)(4) of the Bankruptcy
Code, without further action by Philips. 
 15. Confidentiality. 
 15.1 Definition. “Confidential Information” shall mean all non-public written, visual, oral and electronic data and information disclosed by one Party
(“Discloser”) to the other Party (“Recipient”) under this Agreement that relates to the Discloser’s business, technology, products, processes, techniques, research, development and marketing and is marked as
confidential or proprietary or disclosed under circumstances reasonably indicating that it is confidential or proprietary. All FOSSL IP (that has not otherwise been publicly disclosed or made available, such as described in Section 15.3 below)
shall be Confidential Information of Hansen and Hansen shall be the Discloser (and Philips the Recipient) thereof. All Confidential Information (including without limitation all copies, extracts and portions thereof) shall remain the property of
Discloser. Except as expressly agreed otherwise by the Parties, Recipient does not acquire any intellectual property rights under any disclosure hereunder except the limited right to use such Confidential Information in accordance with this
Agreement. 
 15.2 Restrictions. Recipient shall hold all Confidential Information of Discloser in strict confidence and
shall not disclose any such Confidential Information to any Third Party except as expressly provided in this Section 15.2. Recipient may disclose the Confidential Information of Discloser only to regulatory authorities and employees, agents,
contractors, Affiliates and actual and potential licensees and sublicensees (solely to the extent, in the case of any such licensee or sublicensee, such Confidential Information to be disclosed is licenseable or sublicenseable to such licensee or
sublicensee), in all such cases who have a reason to know such 

  
 38 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
information for purposes of Recipient’s performance of its obligations or exercise of its rights under this Agreement and (except with respect to regulatory authorities) who are bound in
writing by restrictions regarding disclosure and use at least as protective of Discloser as the terms and conditions in this Agreement. Recipient shall not use any Confidential Information of Discloser for the benefit of itself or any third party or
for any purpose other than to perform its obligations and exercise its rights under this Agreement. Recipient shall take at least the same degree of care that it uses to protect its own confidential and proprietary information and materials of
similar nature and importance (but in no event less than reasonable care) to protect the confidentiality and avoid the unauthorized use, disclosure, publication, or dissemination of the Confidential Information of Discloser. 

15.3 Scope. The foregoing restrictions on disclosure and use shall not apply with respect to any Confidential Information of
Discloser to the extent such Confidential Information: (a) was or becomes publicly known through no wrongful act or omission of the Recipient or its Affiliates and their respective employees, agents and representatives; (b) was rightfully
known by Recipient before receipt from Discloser; (c) becomes rightfully known to Recipient from a source other than Discloser without breach of a duty of confidentiality to Discloser or its Affiliates; or (d) is independently developed by
Recipient without the use of or access to the Confidential Information of Discloser. In addition, Recipient may use or disclose Confidential Information of Discloser to the extent (i) approved by Discloser in writing or (ii) Recipient is
legally compelled to disclose such Confidential Information, provided, however, that prior to any such compelled disclosure, if possible, Recipient shall give Discloser reasonable advance notice of any such disclosure and shall cooperate with
Discloser, at Discloser’s cost, in protecting against any such disclosure and/or obtaining a protective order narrowing the scope of such disclosure and/or use of such Confidential Information. 

15.4 Terms of this Agreement. The Parties acknowledge the confidential nature of this Agreement and, except to the extent provided
in Section 15.5 and Section 15.6, neither Party shall disclose the existence or the contents of this Agreement without obtaining the prior approval of the other Party in writing, save as required by applicable law (including as required by the
United States Securities and Exchange Commission) or by either Party in connection with the enforcement of its rights hereunder or on a confidential basis to actual and potential investors or acquirors and legal counsel who are bound by obligations
of confidentiality at least as restrictive as those set forth in this Agreement. Any breach by either Party of any of its confidentiality obligations under this Article 15 shall not affect any right or remedy to which the non-breaching Party would
be entitled at law absent this Agreement. 
 15.5 Press Releases. Notwithstanding any other provision of this Section,
Philips and Hansen may, with prior written consent of the other Party, issue press releases acknowledging that Philips and Philips Affiliates are licensed under the Licensed Patents, provided that the terms of this Agreement are not disclosed. Each
Party agrees to the issuance of the proposed press release attached as Exhibit A. Each Party may disclose any information in such press release (or any subsequent mutually agreed press release or other public announcement) without the additional
consent of the other Party. 

  
 39 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 15.6 Disclosures of Terms to Certain Third Parties. Notwithstanding any other
provision of this Section 15.6, Philips shall be entitled to disclose the existence of this Agreement and the amount of the payment to be made to any Third Party with which Philips has an agreement, arrangement, understanding, or relationship
which permits Philips or the Third Party to seek payment or reimbursement, in whole or in part, of any portion of any of the payments to be made. Before disclosing any information related to this Agreement to such a Third Party, including but not
limited to Philips customers and suppliers meeting the foregoing description, Philips shall obtain agreement from the Third Party that the disclosure shall be on a confidential basis and that the disclosed information shall not be provided to anyone
outside of the Third Party, other than its outside legal counsel. 
 15.7 Limitation of Liability. Except for a breach of
Article 15 (Confidentiality), neither Party shall be liable to the other Party, its employees, directors, shareholders, agents for any indirect or consequential, incidental, punitive or special, damages (including but not limited to damages for
business interruption or for personal injury) arising out of or in connection with this Agreement, even if the other Party has been advised of the possibility of such damages. To the extent either Party is liable to the other Party for any claims
arising out of or in connection with this Agreement, such liability shall be limited to the greater of (a) the amounts owed or paid by Philips pursuant to Sections 3.2, 3.3, and 3.5 and (b) USD 25 Million. 

16. Notices. Any notice required under this Agreement to be sent by either Party shall be given in writing by means of a letter or facsimile
directed: 
 In respect of Hansen, to: 
 A. For notices of a general nature, to: 
 Bruce Barclay - CEO 

Hansen Medical, Inc. 
 800 East Middlefield Road 
 Mountain View, CA 94043 

B. For matters of a general nature: 
 Robert Mittendorff, MD, MBA 
 Hansen Medical, Inc. 

800 East Middlefield Road 
 Mountain View, CA 94043 
 C. For IP/legal matters: 

Arthur Hsieh, JD, PhD 
 Vice President, Legal Affairs 
 Hansen Medical, Inc. 

  
 40 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 800 East Middlefield Road 

Mountain View, CA 94043 
 In respect of Philips, to: 
 Philips Intellectual Property & Standards

 P.O. Box 220 
 5600 AE Eindhoven 
 The Netherlands 

F.a.o. CIPO 
 Fax
no.: + 31 40 27 45267 
 And also to: 
 Philips Healthcare 
 A division of Philips Electronics North America Corp.

 3000 Minuteman Road 
 Andover, MA 01810 
 USA 

Attention: Chief Legal Officer 
 Fax no. : 978-975-1285 
 With a copy to, for technical matters and information
pursuant to Article 8: 
 Nijs C. van der Vaart, PhD, Senior Director Innovation, BU interventional X ray 

Veenpluis 4-6 

5684 PB Best 

The Netherlands 

FAX number: +31 40 27 65657 
 or such other address as may have been specified in writing by either Party to the other. Notice shall be conclusively deemed to have been duly given (a) when hand delivered to another Party;
(b) when sent by facsimile, with receipt confirmation, to the number set forth above if sent between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day, or on the next business day if sent other than between 8:00 a.m. and
5:00 p.m. recipient’s local time on a business day; or (c) the next business day after deposit with an international overnight delivery service, postage prepaid, addressed to the applicable Party as set forth above with next business day
delivery guaranteed, provided that the sending Party receives a confirmation of delivery from the delivery service provider. 
 17. No
Assignment 
 17.1 This Agreement shall be binding upon and inure to the benefit of the Parties and their respective
Affiliates, successors and assigns. This Agreement shall not be assignable by either Party, in whole or in part to any Third Party (subject to Philips’ termination rights under Article 13), except that either Party may assign or transfer this
Agreement, without consent, to 

  
 41 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
(a) an Affiliate of that Party or (b) a purchaser of all or substantially all of such Party’s assets to which this Agreement relates or (c) a successor to such Party’s
business to which this Agreement relates through any merger, consolidation or reorganization; provided in each case that the entity to whom this Agreement is assigned agrees in writing to be bound by the terms and conditions hereof. 

18. Independent Contractors. The Parties are and intend to remain independent contractors. Nothing in this Agreement shall be construed as an
agency, joint venture or partnership between the Parties. 
 19. Applicable Law and Jurisdiction 

19.1 This Agreement shall be governed by and construed in accordance with the laws of New York, without regard or reference to its
conflicts of law rules or principles. 
 19.2 Any dispute between the Parties in connection with this Agreement (including any
question regarding its existence, validity or termination) shall be submitted to the competent courts of The State of New York. 
 20.
Miscellaneous 
 20.1 Force Majeure. If for reasons of Force Majeure, as hereinafter defined, any Party fails to
comply with its obligations hereunder other than the payment of money, such failure shall not constitute breach of contract, provided, however, that such Party shall give the other Party prompt written notice of the failure to perform and the reason
therefor and uses its reasonable efforts to limit the resulting delay in its performance. For the purpose of this Section, Force Majeure shall mean acts of God; war; civil commotion; destruction of production facilities or materials; fire,
earthquake or storm; labor disturbances or strikes; failure of public utilities or common carriers and any other similar causes beyond the reasonable control of any party. 
 20.2 Severability. If any of the provisions of this Agreement is determined to be invalid or unenforceable by any court of competent jurisdiction, such finding shall not invalidate the remainder of
this Agreement which shall remain in full force and effect as if the provision(s) determined to be invalid or unenforceable had not been a part of this Agreement. In the event of such finding of invalidity or unenforceability, the Parties will
endeavor to substitute forthwith the invalid, or unenforceable provision(s) by such effective provision(s) as will most closely correspond with the original intention of the provision(s) so voided. 

20.3 Entire Understanding. This Agreement and any attachments hereto constitute a single, integrated written contract expressing
the entire agreement of the Parties with respect to the subject matter hereof and shall not be modified, supplemented, or repealed except by a writing signed by each of the Parties. No covenants, agreements, representations, or warranties of any
kind whatsoever have been made by any Party, except as specifically set forth in this Agreement. All prior discussions, written communications, agreements and negotiations with respect to the subject matter hereof have been merged and integrated
into and are superseded by 

  
 42 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 
this Agreement. Specifically, with respect to the subject matter hereof, this Agreement supersedes that certain Mutual Nondisclosure Agreement between the Philips Healthcare, a division of
Philips Electronics North America Corporation and Hansen dated April 27, 2009. 
 20.4 Waiver. No waiver by any of
the Parties to this Agreement of any breach of any term, condition or obligation of this Agreement by any other Party shall be construed as a waiver of any subsequent or continuing breach of that term, condition or obligation or of any other term,
condition or obligation of this Agreement of the same or of a different nature. Neither the failure nor the delay of either Party to enforce any provision of, or right or remedy under, this Agreement shall constitute a waiver of such provision,
right or remedy or of the right of each Party to enforce each and every provision of this Agreement. Any waiver of this Agreement must be in writing. 
 20.5 Authority; Due Execution. Each Party represents and warrants to the other, that (i) it has full power and authority to enter into this Agreement and any agreements related hereto and,
subject to the terms and conditions hereof, this Agreement, when executed, will be a valid and legally binding obligation of such Party according to its provisions; (ii) the execution and performance of this Agreement will not constitute a
breach of or an event of default under any agreement, contract, law or regulation to which such Party is or may be bound; and (iii) the execution and performance of this Agreement has been duly authorized by all necessary corporate action.

 20.6 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 20.7 Headings. The headings and
captions used in this Agreement are for convenience only and shall not be considered in construing or interpreting this Agreement. 
 21.
Specific Performance. The rights and remedies of the parties hereto shall be cumulative. The transactions contemplated by this Agreement are unique transactions and any failure on the part of any party to complete the transactions
contemplated by this Agreement on the terms of this Agreement will not be fully compensable in damages and the breach or threatened breach of the provisions of this Agreement would cause the other parties hereto irreparable harm. Accordingly, in
addition to and not in limitation of any other remedies available to the parties hereto for a breach or threatened breach of this Agreement, the parties shall be entitled to seek specific performance of this Agreement and seek an injunction
restraining any such party from such breach or threatened breach. 
 AS WITNESS, the Parties have caused this Agreement to be signed on the date
first written above. 

  
 43 










 CONFIDENTIAL TREATMENT REQUESTED 

 


	
	 FOR HANSEN:
 Hansen Medical,
Inc.

	
	 /s/ Bruce J Barclay

	(signature)
	Name: Bruce J Barclay
	Title: Chief Executive Officer
	
	 FOR PHILIPS:
 Koninklijke
Philips Electronics N.V.

	
	 /s/ Ruud Peters

	(signature)
	Name: Ruud Peters
	Title: Chief Intellectual Property Officer
	
	Philips Medical Systems Nederland B.V.
	
	 /s/ Bert Van Meurs

	(signature)
	Name: Bert Van Meurs
	Title: Senior Vice President
	
	 /s/ John Van Soerland

	(signature)
	Name: John Van Soerland
	Title: Senior Director

 [SIGNATURE PAGE TO PATENT AND
TECHNOLOGY LICENSE AND PURCHASE AGREEMENT] 

  
 44 










 CONFIDENTIAL TREATMENT REQUESTED 

 

 Exhibit A 
 Press Release 
 



 
 Hansen Medical and Philips Enter Agreements for the Development of Non-Robotic 

Applications of Fiber Optic Shape Sensing and Localization Technology 

Hansen to Receive $29 Million Upfront and up to $78 Million in Future Payments 
 MOUNTAIN VIEW, Calif. – February 3, 2011 – Hansen Medical, Inc. (Nasdaq: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of
catheter movement, today announced that it has entered, directly and through a wholly owned subsidiary, into patent and technology license, sublicense and purchase agreements with Philips to allow them to develop and commercialize the non-robotic
applications of Hansen Medical’s Fiber Optic Shape Sensing and Localization (FOSSL) technology. 
 FOSSL is a potentially disruptive
visualization technology that employs a fiber optic sensor designed to allow physicians to identify both the shape and position of catheters and other tools used in minimally invasive procedures. FOSSL has the potential to enable more efficient and
precise control and continuous tracking of flexible tools used in these procedures. Unlike traditional visualization methods, FOSSL is designed to provide visual information in 3D with significant reduction in the use of x-ray. FOSSL is being
developed by Hansen Medical and Luna Innovations, Inc. which are jointly advancing its use in medical applications. 
 Under the
terms of the agreements, Philips has the exclusive right to develop and commercialize the FOSSL technology in the non-robotic vascular, endoluminal and orthopedic fields. In addition, the parties have amended their previous joint development
agreement to allow for Philips to potentially extend and increase certain fees to be paid 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 
by Hansen Medical based on the future sales of the currently investigational flexible catheter vascular robotic system now under development at Hansen Medical with planned commercialization in
the US and Europe in 2011. Hansen Medical will receive upfront payments of $29 million in connection with these arrangements and will be eligible to receive up to an additional $78 million in future payments associated with the successful
commercialization or licensing by Philips or its collaborators of products containing FOSSL technology. 
 “Today’s
announcement is an important milestone in the history of Hansen Medical,” said Bruce Barclay, President and CEO of Hansen Medical. “As a result of the hard work by our talented employees, we have made tremendous strides evolving our
business strategy and focusing on new market opportunities to create a proprietary mode of safe and effective imaging. We are pleased to expand our relationship with Philips, and are now in a position to further develop and commercialize this
technology which has the potential to improve clinical outcomes for future medical products, including to significantly reduce the amount of harmful radiation generated in interventional procedures, all to the benefit of patients, physicians and
hospital staffs. Finally, these agreements allow us to significantly enhance our cash position and strengthen our balance sheet without incurring a dilutive event for our shareholders.” 
 “These agreements represent a considerable step forward in the relationship between Hansen Medical and Philips Healthcare in bringing innovative technology solutions to patients and physicians in
multiple medical fields from orthopedics to interventional procedures. We are delighted to be moving forward with Philips on both the application of the FOSSL technology outside of robotics and on the advancement of our robotics technology for
vascular procedures,” said Robert Mittendorff, M.D. Vice President of Marketing and Business Development at Hansen Medical. 
 While
minimally invasive procedures have advanced significantly in the past 30 years, their potential is still limited by imaging and localization, which remain critical elements to knowing 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 
where flexible tools are in the body. Since the incision is so much smaller than typical open surgery and direct visualization is not possible, physicians have to rely on X-ray imaging or
localization to know where their instruments are and the shape of the instruments they are manipulating. Significant radiation exposure to the patient and physician is often the result, and usually provides only two dimensional information. With
FOSSL enabled devices, the potential benefits to patients and the physicians that treat them are substantial, including increased efficiency, control and reduced use of radiation in minimally invasive procedures. 

Hansen Medical Conference Call 
 Company
management will hold a conference call to discuss its new agreements with Philips today, February 3, 2011, at 5:30 a.m. Pacific (8:30 a.m. Eastern). Investors are invited to listen to the call live via the Internet using the link available
within the “Investor Relations” section of Hansen Medical’s website at www.hansenmedical.com. A replay of the webcast will be available approximately one hour after the completion of the live call. Additionally, participants can dial
into the live conference call by calling 877-941-2321 or 480-629-9714. An audio replay will be available approximately one hour after the completion of the conference call through February 3, 2011, by calling 877-870-5176 or 858-384-5517, and
entering access code 4379093. 
 About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based
technologies. The company’s Sensei® system and its Sensei X Robotic Catheter System were cleared by the
U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram
data. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei and Sensei X systems
for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established during EP procedures, such as guiding catheters in the treatment of AF. In the European Union, the Sensei
and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF. The flexible catheter vascular robotic system requires regulatory filings and approval and is not commercially available. Additional
information can be found at www.hansenmedical.com. 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 Forward-Looking Statements 
 This press release contains forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hansen
Medical’s results to differ materially from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including
statements containing the words “plan,” “expects,” “ believes,” “potential,” and similar words. Hansen Medical intends such forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements regarding expectations for the commercialization of the FOSSL
technology and our flexible catheter vascular robotic system. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include, among others, the realization of the full potential
benefits of the agreements with Philips requires the development of new products and applications of technology that are subject to design, engineering and manufacturing challenges, potential safety and regulatory issues that could delay, suspend or
terminate clinical studies, regulatory approvals or sales, and reliance on third parties to develop, obtain regulatory approval for, manufacture, market and sale of products containing FOSSL technology. These and other risks are described in greater
detail under the heading “Risk Factors” contained in our periodic SEC filings, including our Quarterly Report on Form 10-Q filed with the SEC on November 9, 2010. Given these uncertainties, you should not place undue reliance on the
forward-looking statements in this press release. Hansen Medical undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. 

Hansen Medical, Heart Design, Hansen Medical & Heart Design, and Sensei are registered trademarks of Hansen Medical, Inc. in the United States
and other countries. 
 Hansen Medical Contacts: 
  

					
	Peter Osborne	 		  	Matt Clawson
	Interim CFO	 		  	Allen & Caron Inc.
	Hansen Medical	 		  	949.474.4300
	650.404.5800	 		  	matt@allencaron.com

 # # # # 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT B 
 Listed Patents and Patent Applications within Licensed Luna Patents 
 [***] 

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT C 
 Certain Luna Technology within Licensed Luna IP 
 [***] 

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT D 
 [***] 
 [***] 

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT E 
 Hansen Group 1 Patents 
  

									
	 Title
	 	 Inventors
	 	 App

No.
	 	 Filing

Date
	 	 Related Family of
Patent
Applications


 [***] 

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT F 
 Hansen Group 2 Patents 
  

									
	 Title
	  	 Inventors
	  	 App

No.
	  	 Filing Date
	  	 Related Family of Patent

Applications



[***] 

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT G 
 Hansen Group 3 Patents 
  

									
	 Title
	  	 Inventors
	  	 App

No.
	  	 Filing

Date
	  	 Related Family of

Patent Applications


 [***] 

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 Exhibit H 
 List of Hansen Agreements Provided by Hansen to Philips for Philips’ Review 
 1.
License Agreement No. DN-982 by and between the United States of America (NASA) and Luna Innovations Incorporated dated June 10, 2002, including the modification dated January 23, 2006 

2. Development and Supply Agreement between Hansen and Luna Innovations, Inc. dated January 12, 2010, as amended pursuant to Amendment No. 1 to
Development and Supply Agreement dated as of February 17, 2010 and Amendment No. 2 to Development and Supply Agreement dated as of April 2, 2010 
 3. Development and Supply Agreement dated June 11, 2007 between Intuitive and Luna Innovations Incorporated, as restated and amended by Luna and Intuitive as of January 12, 2010 

 

	4.	Cross License Agreement between Intuitive Surgical, Inc. and Hansen, effective as of January 12, 2010. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 EXHIBIT I 
 Silicon Valley Bank Consent 
 [To be attached.] 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 Annex 1: Royalty Reporting Form 

[Licensor] 
 Name: 

Department: 
 Address: 

Fax: [number] 
 Koninklijke Philips Electronics
N.V. [other Philips entity] 
 P.O. Box 220 
 5600 AE Eindhoven 
 The Netherlands 
 Fax no.: + 31 40 27 45267 
 Date: 
 Koninklijke Philips Electronics N.V. 
 Manufacturing site [Philips entity] 

City: 
 Country: 

Reference: Royalties 
 This is to provide you with our royalty statement under the Patent License and Assignment Agreement of February 3, 2011 between our companies, which covers the relevant business of FOSSL Systems for
the [1st, 2nd]
calendar half of [year]. The total fee is to be calculated in accordance with [reference]. 
  

											
	 FOSSL System,
 (serial number)
	  	 Description
	  	 Units Sold
	  	 Calculation

of Applicable

Royalty Amount
	  	 	  	 Total Royalty

fee due in Euro

						
		  		  		  		  	Gross amount due	  	
						
		  		  		  		  	Less withholding tax (if applicable)	  	
						
		  		  		  		  	Net amount due	  	

 I attest that the above is true, complete and accurate. 
 Signed on behalf of [Licensee]. 
 Name: 
 Title: 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 Annex 2: Assignment Form 

D E E D O F A S S I G N M E N T 
 This ASSIGNMENT made the .second day of February Two thousand eleven 
 BETWEEN

 HANSEN MEDICAL, INC., a corporation having its registered office at 800 East Middlefield Road, Mountain View, CA 94043, USA (hereinafter
“Assignor”) of the other part, 
 and 
 KONINKLIJKE PHILIPS ELECTRONICS N.V., a company duly incorporated under the laws of The Netherlands, having its registered office in Eindhoven, The Netherlands (hereinafter “Assignee”) of the
one part, 
 WHEREAS, Assignor and Assignee have entered into that certain Patent and Technology License and Purchase Agreement dated
February 3, 2011 (“License and Purchase Agreement”), 
 This Deed of Assignment is to confirm the following: 

Assignor is the registered proprietor of the United States and foreign patents and patent applications listed on the attached Schedule 1 having the
titles set forth thereon (hereinafter “Patent rights”) 
 In consideration of a sum of or equivalent to at least $1 (one US dollar)
and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, subject to the terms and conditions of the License and Purchase Agreement, Assignor has assigned to Assignee all right, title and interest in
and to the Patent rights and Assignee has accepted said assignment. 
 Assignor hereby grants full power of attorney to Assignee to submit this
Deed of Assignment to the patent authorities of the United States and other jurisdictions in which such Patent rights may obtain and to request those authorities to record the assignment of the legal title to the Patent rights from Assignor to
Assignee in the appropriate registers provided that, where possible, any retained license to Assignor and its Affiliates shall be simultaneously recorded in those registers. 








 CONFIDENTIAL TREATMENT REQUESTED 

 


					
	EXECUTED for and on behalf of	 		 	 EXECUTED for and on behalf of

	KONINKLIJKE PHILIPS	 		 	 HANSEN MEDICAL, INC.

	ELECTRONICS N.V.	 		 	
			
	  
	 		 	  

	Authorized Representative	 		 	 Authorized Representative


 [Signature Page for Deed of Assignment] 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 Schedule 1 to Annex 2 (Assignment Form) 

Patent rights 
  

									
	 Title
	  	 Inventors
	  	 US App

No.
	  	 Filing

Date
	  	 Published Applications
and
Issued Patents for Patent Family


 [***] 

  
 [***] CONFIDENTIAL
PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION.